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Abstract 
 The pili of P. aeruginosa 1244 are involved in a post-translational modification in which 
an acidic carbohydrate moiety structurally similar to the lipopolysaccahride (LPS) O-antigen is 
covalently attached to the pilin protein.  It has been shown that this associated glycan is evenly 
distributed over the entire surface of the pilus.  Because of its prime location along the pilus, 
experiments were conducted to determine if the pilin glycan contributed to the virulence of P. 
aeruginosa.  Initial studies involved the assessment of LD50 values to demonstrate that 
acquisition of the exoU gene increased the virulence of PA1244.  Interestingly, the LD50 studies 
suggested a role for the pilin glycan in PA1244 virulence.  As a more sensitive determination of 
virulence, a competition assay utilizing a murine model of acute pneumonia demonstrated 
increased virulence associated with the glycan.  Furthermore, employment of a nonopsonic 
phagocytosis assay has indicated inhibition of phagocytosis correlated with the pilin glycan. 
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I. Introduction 
A. General Characteristics of Pseudomonas aeruginosa 
Pseudomonas aeruginosa is a Gram-negative, rod-shaped opportunistic pathogen  
belonging to the family Pseudomonadaceae (Stanislavsky et al., 1997).  In 1882, this facultative 
pathogen was first isolated and named Bacillus pyocyaneus (Gessard, 1882).   The species name, 
pyocyaneus, was based upon one of the two pigments that Gessard found in the bacterium – the 
pyocyanin pigment.  Pyocyanin is a water-soluble green phenazine pigment that causes the 
growth medium of Pseudomonas to acquire a bluish-green tint (Odeh et al., 2000).  Today, the 
bacterium is better known as Pseudomonas aeruginosa.  Figure 1 illustrates a typical micrograph 
of P. aeruginosa stained with crystal violet.  
P. aeruginosa is well known for being a ubiquitously distributed prokaryote.  It has been 
known to inhabit a variety of hosts such as plants, insects, nematodes, and humans (Jander et al., 
2000; McGrath et al., 2004).  This organism is extremely versatile due to its capability to utilize 
various environmental compounds as energy sources, its large genome size, and its genetic 
complexity.  P. aeruginosa can colonize in niches with a limited amount of resources by utilizing 
compounds readily available in the environment for energy.  In addition, the large genome size 
and genetic complexity of P. aeruginosa make it able to withstand various conditions (Stover et 
al.,  2000).  The complexity of this microorganism is seen when analyzing its sequence.  The P. 
aeruginosa genome consists of 6.3 million base pairs.  Within this large genome is located the 
highest proportion, 8.4% of the entire genome, of regulatory genes observed for a bacterial 
genome (Stover et al., 2000).  Possessing a large number of regulatory genes is associated with 
the ability to activate different survival mechanisms that coincide with changing environmental 
conditions.  Also, the complexity of the P. aeruginosa genome can be seen when comparing the 
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open reading frames (ORF’s) of this prokaryote with the ORF’s of Saccharomyces cerevisiae, a 
eukaryote.  P. aeruginosa has 5,570 ORF’s and S. cerevisiae has 6,200 ORF’s (Stover et al., 
2000).  Having a comparable amount of ORF’s to a eukaryote suggests that P. aeruginosa has 
more developed and more complex survival mechanisms than most prokaryotes. 
Because P. aeruginosa is found in a wide-range of habitats, it is very likely that humans 
come into contact with this bacterium on a daily basis.  This normal day-to-day co-existence with 
the microorganism allows the human body to develop a high titer and resistance to P. aeruginosa 
infections.  In fact, a bacterial infection associated with this organism is extremely rare in healthy 
individuals.  If a P. aeruginosa infection were to arise in a person who is in relatively good 
health, the non-specific immune system would be able to rid the body of the bacterium.  
Unfortunately, not everyone has this type of reaction to a P. aeruginosa infection.  This 
microorganism poses a traumatic danger to those who have pulmonary disease or who are 
immunocompromised (Bodey et al.,1983).  The immune systems of these individuals are under 
great stress from their pre-existing ailment.  With the addition of this new infliction, the victim’s 
immune system cannot adequately fight the bacterial infection.  
  
 
                                                                                              
                                                                            
 
 
               
Figure 1. Micrograph of Pseudomonas 
aeruginosa 1244.  P. aeruginosa stained 
with crystal violet (100X).  Note the 
distinct rod shape of the bacterium.  
(Roguskie, present research) 
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B. P. aeruginosa’s Prevalence in the Medical World 
 Although Pseudomonas is capable of inhabiting a plethora of niches, most P. aeruginosa 
isolates have been associated with hospitals.  In fact, the bacterium is responsible for 10-20% of 
infections in most hospitals, affecting patients suffering from burns, organ transplant recipients 
and cystic fibrosis victims (Bodey et al., 1983).  Pseudomonas was ranked the second most 
frequent pathogen in surgery and the third most frequent in medicine (Bodey et al., 1983).  P. 
aeruginosa was the most common pathogen recovered from patients that were hospitalized for 
more than one week (Bodey et al., 1983).  It is among the most frequently isolated 
microorganisms found in pus, sputum, blood, and other bodily fluids from patients with Gram-
negative hospital infections.  Pseudomonas has been isolated from soil, plants, sinks, faucets, 
bedpans, catheters, respirators, bladder irrigation devices, and other moist areas in hospital 
settings (Botzenhart et al., 1993).   
 Nearly all clinical cases of P. aeruginosa infections can be associated with the 
compromise of host defense.  For instance, normal dry skin does not support the growth of P. 
aeruginosa; however, infections are frequent in surgical wounds, burns, and on other exposed, 
vulnerable tissues (Dale et al., 2004).  The natural immune defenses, in this case the skin serving 
as a protective barrier, are weakened.  In these situations, the skin is often moist and provides an 
ideal environment for P. aeruginosa to colonize and initiate infection.  The bacterium can then 
rapidly disseminate from the burn or surgical wound site into distant organs via the bloodstream 
leading to a bacterial infection of the blood known as septicemia.  Once the blood is infected, the 
individual will enter a state known as endotoxic shock.  Endotoxic shock involves the lowering 
of blood pressure as well as blood flow.  In addition, endotoxic shock is often accompanied by 
inflammation as a result of the toxins secreted by the bacterium.  Once in endotoxic shock, the 
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patient usually proceeds to death (Dale et al., 2004).  Some common P. aeruginosa skin 
infections include: “green nail” syndrome, toe web infection, Pseudomonas pyoderma, 
Pseudomonas cellulitis, and ecthyma gangrenosum (Bodey et al., 1983).  
 In addition, persons receiving organ transplants are at risk of succumbing to a P. 
aeruginosa infection.  Bacteremia, which is the presence of viable bacteria in the blood, is the 
most recurrent infectious complication associated with liver transplantation (Singh et al., 2004).  
Furthermore, P. aeruginosa infections are efficient in causing both minor and serious infections 
of the eyes, ears, nose and throat.  P. aeruginosa is the most common Gram-negative bacterium 
causing corneal ulcers.  The greatest risk of a corneal infection lies with those individuals 
suffering from cancer or thermal burns on the eyes.  These infections are characterized by a 
greenish pus and a hypopyon (Bodey et al., 1983).  A hypopyon is the fluid level of pus present 
during an infection located in the anterior chamber of the eye.  Also, contact lens wearers should 
be wary of a Pseudomonas infection (Micallef et al., 1999).  An opportunity for P. aeruginosa to 
cause infection arises from small scratches created on the cornea caused by improper use of 
contact lenses.  Also, eye infections often result from storing contact lenses in contaminated 
contact lens cases (Micallef  et al., 1999).   As for ear infections, P. aeruginosa causes 
approximately 70% of the cases of otitis externa (Bodey et al., 1983).  The most common ear 
infection correlated with Pseudomonas is “swimmer’s ear.”  The most traumatic Pseudomonas 
infection of the ear is known as malignant otitis externa.  This type of infection is generally 
found in the elderly and in diabetics.  Some symptoms associated with a P. aeruginosa ear 
infection include: persistent pain of the ear, severe edema, tenderness of the soft tissues of the 
ear, and purulent drainage (Bodey et al., 1983).  Besides causing devastating damage to the eye 
and ear, P. aeruginosa is associated with throat and mouth infections.  Nosocomial sinusitis is an 
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example of a nasopharyngeal disease caused by Pseudomonas.  An infection of this sort is 
typically resolved by removal of all nasal tubes and treatment with antibiotics and decongestants 
(Bodey et al., 1983).   
 In continuing, P. aeruginosa is responsible for a number of infections in vital organs 
as well as in the skeletal system.  One organ that is of particular interest is the lung.  P. 
aeruginosa, when in the setting of a preexisting epithelial injury, can cause infection in the lung 
leading to severe acute pneumonia (McMorran et al., 2003).  In an intensive care unit, 40% of 
the mortalities resulting from a P. aeruginosa infection are from pneumonia (McMorran et al., 
2003).   This is a significant percentage of the population who are infected by this bacterium that 
is dying from lung failure.  In support of this statistic, studies have shown that P. aeruginosa is 
most frequently the dominant pathogen that results in a decline in pulmonary function (Lanotte et 
al., 2003).    Cystic fibrosis (CF) is a preexisting disease that is commonly associated with P. 
aeruginosa induced acute pneumonia.  Cystic fibrosis is the most common life-shortening 
autosomal recessive disorder in populations of European origin.  It is caused by mutations in the 
cystic fibrosis transmembrane conductance regulator (CFTR) gene located on chromosome 7 
(Rosenstein et al., 1998).  CFTR normally functions as a cyclic AMP-regulated chloride channel 
of epithelial cells lining the airways, intestines, and exocrine glands.  Mutations interfere with 
chloride transport leading to the buildup of a viscous mucous in the lungs.  The presence of this 
mucous provides a perfect environment in which P. aeruginosa can thrive and promote infection.  
In a healthy individual, P. aeruginosa is not a problem.  The lung airways normally remain 
sterile through the action of the mucociliary escalator, secretion of antibacterial factors and the 
actions of patrolling macrophages.  When suffering from cystic fibrosis, these immune defenses 
are compromised and the upper airways become colonized with pathogens (Hybiske et al., 
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2004).  Ultimately, 80% to 95% of patients suffering from CF succumb to respiratory failure 
brought on by bacterial infection and concomitant airway inflammation (Lyczak et al., 2002). 
 Besides the lungs, Pseudomonas infects the heart, the gastrointestinal tract, the brain, the 
spinal cord, the urinary tract, and the blood.  In the heart, a P. aeruginosa infection results in 
endocarditis (Bodey et al., 2003).   Inside the gastrointestinal tract, Pseudomonas was found to 
be the perpetrator in occurrences of ulcerations, diarrhea, and typhilitis (Bodey et al., 1983).  A 
P. aeruginosa infection of the brain and spinal cord is known as meningitis.  As for the urinary 
tract, the majority of Pseudomonas infections are acquired during hospitalization following the 
insertion of a catheter or some other sort of genitourinary manipulation (Bodey et al., 1983).  
Unusual, yet frequent, infections of the bones and joints result from colonization by this 
opportunistic bacterium.  Osteomyelitis and osteoarthritis are two common afflictions linked to a 
P. aeruginosa infection of the bones.  Lastly, the blood of an immunocompromised individual 
may become infected with this Gram-negative pathogen resulting in septicemia.  The frequency 
and prognosis of Pseudomonas related septicemia is determined by the patient’s underlying 
disease.  Patients suffering from leukopenia, immunoglobulin deficiency, and renal failure who 
are also experiencing septicemia onset by Pseudomonas usually have a poor prognosis (Bodey et 
al., 1983).   
 One of the primary reasons P. aeruginosa is such a deadly bacterium is because of its 
inherent resistance to a wide variety of drugs and its ability to acquire resistance to all effective 
antibiotics.  Being a Gram-negative bacterium, P. aeruginosa is resistant to a larger number of 
antibiotics and chemotherapeutic drugs than are Gram-positive bacteria (Nikaido, 1998).  The 
outer membrane of Gram-negative bacteria acts as a permeable barrier.  Narrow porin channels 
located throughout the outer membrane restrict the penetration of hydrophilic solutes.  In 
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addition, the lipopolysaccharide (LPS), a virulence factor of P. aeruginosa that will be discussed 
in great detail on the following pages, plays a role in protecting the bacterium from antibiotics.  
Because of its low fluidity nature, the LPS inhibits the inward diffusion of lipophilic solutes—in 
this case, antibiotics.  Moreover, there is yet another factor that contributes to the antibiotic 
resistance of Pseudomonas.  From the moment the antibiotic is in the periplasm to the time it 
reaches the surface of its target bacterium (approximately 10-20 seconds), the concentration of 
the antibiotic usually decreases by 50% of its original strength (Nikaido, 1998).  This is due to 
the presence of periplasmic β-lactamases and active efflux pumps.  Β-Lactams account for 
approximately 50% of global antibiotic consumption (Livermore, 1998).  These enzymes 
degrade important compounds comprising the antibiotic.  Efflux pumps that transverse the inner 
and outer membrane allow the bacterium to pump out any antibiotic that has permeated the cell 
membranes (Nikaido, 1998).  Two types of multi-drug efflux pumps have been identified in 
Gram-negative bacteria.  The first type involves the transport of drugs into the periplasmic space.  
The second type of efflux pump directs the antibiotic directly into the medium (Nikaido, 1998).  
Presenting the microorganism with a decreased concentration of antibiotic increases the chances 
that the bacterium can overcome it.   
 Although most strains of P. aeruginosa have developed resistance to the commonly used 
antibiotic treatments, a small group of antibiotics are still beneficial in treating a P. aeruginosa 
infection.  According to a study conducted in 2003, an antibiotic combination consisting of an 
imipenem-cilastin cocktail was the most effective antibiotic treatment.  Only 7.5% of the P. 
aeruginosa strains tested in that study showed resistance to this drug combination (Pirnay et al., 
2003).   The antibiotic with the highest in vitro activity is piperacillin-tazobactam (Martinez et 
al., 2003).  Furthermore, there has been research conducted that suggests a drug combination of 
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tobramycin and high-dose meropenem and/or ceftazidime will be effective in fighting off P. 
aeruginosa infections (Conway et al., 2003).  Amikacin is another antibiotic that may be useful 
in treating a Pseudomonas infection.  Fewer than 22% of individuals suffering from a P. 
aeruginosa infection demonstrated resistance to amikacin.  In order to better understand P. 
aeruginosa and find an antibiotic that is effective in eradicating an infection, researchers are 
studying the mechanisms of the many virulence factors of the bacterium.  Of particular interest to 
current research are quorum sensing and biofilm formation.  Quorum sensing is defined as the 
communication between cells.  A biofilm is a sticky layer of bacterial cells involved in the 
colonization of a host.  These two virulence factors are studied in conjunction due to the role 
quorum sensing plays in biofilm formation.  In order to establish a biofilm, the bacterial cells 
must communicate with each other.  A biofilm formed by P. aeruginosa is resistant to the action 
of antimicrobial agents such as commercial cleaners commonly utilized in hospitals (Stephens, 
2002).  Having a thick, highly dense layer of cells, or biofilm, inhibits antibiotics from working 
effectively.  These two virulence factors involved in the pathogenesis of P. aeruginosa will be 
discussed at a later time.   
C. The Virulence Factors of Pseudomonas aeruginosa 
1. Cellular Virulence Factors 
 P. aeruginosa is able to sustain itself inside a host due to its many virulence factors.  P. 
aeruginosa synthesizes both cellular and extra-cellular products to aid in its ability to cause 
infection and colonize in the host cell.  Some cellular products include lipopolysaccharide (LPS), 
alginate, and pili.  As a Gram-negative bacterium, the LPS layer is one of the most recognized 
virulence factors.  The LPS has been shown to elicit a nonspecific immune response, such as 
inflammation, in immunocompromised patients (Wieland et al.,  2002).  Because of its 
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immunogenic ability, the LPS can be considered as a target when developing a P. aeruginosa 
vaccine.  The role of LPS has also been extended to acting as an adhesin in binding to epithelial 
cells and as a glycolipid GM1 receptor of the host cell (Gupta et al., 1994).  Its role in adhesion 
is due to the location of the LPS in the outer stratum of the outer membrane enabling the LPS to 
interact with its environment.  The lipopolysaccharide layer consists of three distinct structural 
regions: the lipid A backbone, an oligosaccharide core, and the O-polysaccharide outer region 
(the O-antigen) (Bennett-Guerrero et al., 2000).  A representation of the three structural regions 
can be seen in Figure 2.  The lipid A backbone serves as a hydrophobic membrane anchor and is 
the toxic component of the LPS.  The lipid A backbone region of the LPS is comprised of two 
glucosamine-phosphate moieties bound to lipid chains.  The O-antigen is attached to lipid A via 
the core region.  The O-antigen is the major contributor to the antigenic variability of the 
bacterial cell surface.  The lipid A region, as well as the O-antigen, is synthesized on the 
cytoplasmic portion of the inner membrane (Bos et al., 2004).  In order to function properly, 
lipid A must be translocated from the cytoplasmic side of the inner membrane to the periplasmic 
side.  An ATP-binding cassette family transporter protein known as MsbA is responsible for the 
transport of the lipid A moiety to the periplasmic side of the inner membrane.  Likewise, it is 
necessary for the O-antigen to utilize a sophisticated transport mechanism in its translocation 
from the cytoplasmic surface of the inner membrane to the periplasmic surface of the inner 
membrane.  Although the specific details of how a fully assembled LPS is transported through 
the periplasm and across the outer membrane are elusive, recent work suggests the involvement 
of an outer membrane protein Omp85 (Bos et al., 2004).  Once present on the outer membrane, 
the LPS of P. aeruginosa can usually be expressed as two unique types: A-band and B-band.  
The P. aeruginosa A-band LPS is a neutral homopolymer of [-α-D-rhamnose]3.  The B-band is a 
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heteroploymer formed by uronic acid derivatives and atypical sugars such as pseudaminic acid 
(Lins et al.,  2001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 2. The Lipopolysaccharide (LPS) of Pseudomonas aeruginosa.  The LPS is 
composed of three distinct regions: lipid A, the core region, and the O-antigen.  
(http://pathmicro.med.sc.edu/fox/cell_envelope.html.)  
 
  
 Due to its role as an adhesin and an immunogen, the lipopolysaccharide is associated 
with P. aeruginosa pathogenicity.  An example of the role the lipopolysaccharide of P. 
aeruginosa plays in virulence can be seen in a patient who is victim to both cystic fibrosis and a 
P. aeruginosa infection.  When infected, the outer core of the LPS specifically binds to the cystic 
fibrosis transmembrane conductase regulator (CFTR; a component involved in various 
trafficking mechanisms).  Once this interaction has been established, the CFTR has been shown 
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to initiate the innate immunity.  The bacteria begin to get internalized and eliminated via cellular 
desquamation.  In addition, the attachment of the LPS to the CFTR leads to rapid NF-κB nuclear 
translocation (Schroeder et al., 2002).   NF-κB is a rapid response nuclear transcription factor 
involved in immune and inflammatory reactions.  It exerts an effect by expressing cytokines, 
chemokines, cell adhesion molecules, growth factors, and immunoreceptors.  By undergoing NF-
κB nuclear translocation, the immune system of the host will be activated and the bacteria will 
soon be destroyed.  Undoubtedly, P. aeruginosa provides a challenge to the immune system.  
The LPS, specifically lipid A, influences the outcome of the bacterium/immune system face-off.  
Bacteria possessing lipid A demonstrate resistance against cyclic adenosine monophosphate 
(cAMP) as well as other membrane components of the host immune system.  The function of 
cAMP is to carry signals from the cell surface to proteins within the cell stimulating protein 
kinases.  By demonstrating resistance to cAMP, the bacteria inhibit any signaling that would 
stimulate parts of the host immune system.  This benefits the bacterium by enhancing survival 
and colonization inside the host (Ernst et al., 1999).   
 Alginate, another cellular product of P. aeruginosa that functions in virulence, is a 
mucoid polysaccharide consisting of a linear polymer of O-acetylated β-1,4-linked D-
mannuronic and L-guluronic residues.  This specific virulence factor contributes to P. 
aeruginosa’s pathogenicity by forming a slime coating on the bacterial cells.  This coating 
protects the bacterium from antibiotics and phagocytosis (Preston et al., 2000).  It allows for a 
situation in which the polysaccharide coating acts as a barrier preventing the immune system and 
any other unfavorable conditions from destroying the bacteria.  In addition, having an alginate 
slime coat also provides protection for the bacterium when subjected to oxidative stress.  
Moreover, this unique virulence factor can act as an adhesin which enables bacterial colonization 
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of the respiratory tract (Hentzer et al., 2001).  The characteristic that makes alginate so unique is 
that the genes involved in biosynthesis are usually silent.  In fact, to save energy, alginate is only 
produced when needed.  In order to become activated, the alginate biosynthetic genes require 
sensing of environmental signals and an intricate regulatory circuitry in the lung.  With the 
exception of algC, the structural genes that encode alginate biosynthesis are clustered within an 
18 Kb operon located at 34 minutes of the P. aeruginosa chromosome (Gacesa, 1998).   
 The final cellular virulence factor that will be discussed is the pilus.  The pili of P. 
aeruginosa are crucial for motility and adherence to host cells (Power et al., 2003).  The pili, 
which are classified as type IV pili, enable the bacterium to move around on the surface of the 
host epithelial cell allowing for infection to spread.  These fascinating structures will be 
discussed in greater detail on the following pages. 
 2. Extracellular Virulence Factors 
 Once P. aeruginosa is inside the host and has adhered to epithelial cells, the bacterium 
secretes extracellular molecules that cause extensive damage to the host’s tissues.  These 
extracellular substances include proteases, hemolysins, and a variety of exotoxins secreted by 
either a type II or a type III secretion system.  Two zinc metalloproteases that are associated with 
P. aeruginosa virulence are elastase (LasB) and alkaline protease (AP).  These proteases are 
involved in the production of hemorrhagic lesions, necrosis, and destruction of non-specific host 
defenses (Stanislavsky et al., 1997).  Elastase is responsible for the degradation of several 
biologically important substrates including elastin, collagen, immunoglobulins, transferrin and 
lactoferrin, complement components and α1-antiproteinase inhibitors.  Elastase promotes the 
pathogenicity of P. aeruginosa by allowing for intra-alveolar hemorrhaging and necrosis by 
solubilization of elastin-containing human lung tissue and degradation of laminin and elastin 
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vascular tissue (Sokol et al., 2000)  This virulence factor also enables dissemination by 
destroying barriers present in the host that would normally inhibit the spread of the bacteria.  
Furthermore, recent studies have shown elastase to cleave transferrin and release iron.  This 
cleavage results in the generation of hydroxyl radicals at the site of the P. aeruginosa infection 
contributing to host tissue injury (Sokol et al., 2000).   It has also been determined that elastase 
inhibits monocyte chemotaxis (Lyczak et al., 2000).  This may be due to the role that elastase 
plays in degrading many biologically important substrates.  It is probable that these substrates are 
needed in chemotaxis.  Overall, elastase contributes to the pathogenicity of P. aeruginosa by 
posing a challenge to the phagocytes and other components of the immune system.  
 Another extracellular molecule functioning in the pathogenicity of P.aeruginosa is 
alkaline protease (AP).  Alkaline protease is a 50.4 kDa zinc-dependent metalloprotease.  This 
virulence factor is responsible for cleaving a number of immunologically important molecules in 
vitro such as complement components C1q and C3 and proinflammatory cytokines interferon 
gamma (IFN-γ) and TNF-α (Pillar et al., 2000).  Alkaline protease has been associated with 
virulence in P. aeruginosa corneal infections.  Experimentation has been conducted in order to 
determine the precise role of this virulence factor in a corneal infection, specifically AP’s role in 
keratitis.  After constructing isogenic mutants lacking alkaline protease, researchers 
demonstrated that this virulence factor is not a necessity in establishing an infection in the cornea 
(Pillar et al., 2000).  Keratitis persisted with a P. aeruginosa strain that lacked alkaline protease.   
 The final protease that will be discussed that enhances the virulence of this Gram-
negative pathogen is protease IV.  Protease IV is a P. aeruginosa lysine-specific protease with a 
molecular mass of 26-kDa (Traidej et al., 2003).  Studies have shown protease IV to degrade 
several biologically important molecules including C3, C1q, IgG, fibrinogen, plasmin, and 
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plasminogen.  Also, it has been associated with Pseudomonas keratitis and is capable of 
degrading corneal epithelium (Caballero et al., 2001).  This specific role was determined by 
inserting a plasmid carrying an active protease IV gene into a protease IV deficient mutant.  The 
strain was then tested for its ability to grow and induce corneal virulence.  Amazingly, this 
rescued strain (the strain containing the plasmid) demonstrated the same virulence of a parent 
strain (wild type strain already possessing the gene for protease IV) that had a known role of 
increasing P. aeruginosa virulence as seen in keratitis (Caballero et al., 2001).    
 The hemolysins that contribute to the virulence of P. aeruginosa are phospholipase C and 
rhamnolipid.  These two enzymes work as a team in destroying the lung tissue.  In the case of a 
P. aeruginosa infection, rhamnolipid released by the bacterium solubilizes the hydrocarbons 
found in the host cell membrane while phospholipase C degrades them (Bodey et al., 1983; 
Heurlier et al., 2004).  Rhamnolipids are biosurfactants that function as heat-stable hemolysins.  
These biosurfactants enhance bacterial surface translocation by virtue of their wetting properties.  
Rhamnolipids lower the surface tension and facilitate the spreading of bacteria on semisolid 
surfaces.  P. aeruginosa produces two known forms of phospholipase C (PLC).  One known PLC 
is hemolytic and one is nonhemolytic.  Studies have shown that the nonhemolytic PLC has no 
pathogenic activities whereas the hemolytic PLC demonstrates prolific devastation.  When 
injected into mice, the hemolytic PLC causes increased vascular permeability, end organ 
damage, and death.  In addition, phospholipase C hydrolyzes phosphatidycholine, a major 
component of the lung surfactant, into diacylglycerol (DAG) and choline.  Studies have shown 
that the presence of DAG activates protein kinase C in eukaryotic cells eventually leading to an 
inflammation response (Wieland et al., 2000).   
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 In addition to the hemolysins and proteases utilized by P. aeruginosa, this Gram-negative 
bacterium also employs a type III secretion system (TTSS) that couples secretion with 
pathogenesis.  This type of secretion system allows the bacterium to inject toxins directly into the 
host cell.  Injecting toxins directly into the host rather than secreting extracellular toxic 
molecules proves far more effective in contributing to the pathogenicity of the bacterium.  The 
TTSS export mechanism is composed of more than 20 different proteins including soluble 
cytoplasmic proteins, outer membrane proteins, and integral membrane proteins (Lyczak et al., 
2000).  Figure 3 provides a typical representation of a type III secretion system.  Employment of 
this TTSS has been associated with evasion of the host immune system.  Recent studies have 
demonstrated that some cystic fibrosis isolates of P. aeruginosa are able to resist the bactericidal 
activity of polymorphonuclear leukocytes (PMN’s) and induce rapid TTSS-dependent oncotic 
cell death of both PMN’s and macrophages (Dacheux et al., 2002).  In order to effectively avoid 
the host immune system, these proteins must be processed.  The proteins, or exotoxins, secreted 
via the type III secretion system are not subject to amino-terminal processing during secretion.  
Rather, the signal for secretion resides within the amino-terminal 15-20 amino acids.  It has been 
shown that in some cases, protein secretion is regulated by contact with the surface of a target 
cell.  The initial step in the activation of the expression of the TTSS genes in P. aeruginosa is the 
upregulation of the transcription of the exsA gene.  ExsA is upregulated in response to different 
environmental stimuli such as calcium depletion in vitro or target cell contact in vivo.  A study in 
2002 showed that expression of ExsA in trans was sufficient to activate in vitro secretion and ex 
vivo cytotoxicity toward phagocytes in noncytotoxic cystic fibrosis isolates (Dacheux et al., 
2002).  In continuing, the TTSS assembles supermolecular structures on the bacterial surface.  It 
has been suggested that these structures are involved in protein translocation into eukaryotic cells 
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(Dacheux et al., 2002).  A trademark of type III secretion is that the usual secretion of some 
substrate proteins requires the presence of a small cytosolic chaperone.  In general, the 
chaperones are encoded by a gene located in close proximity to the gene encoding the protein 
that they assist (Cornelis et al., 2000).  Some of the exotoxins secreted by the type III secretion 
system of P. aeruginosa include exotoxins S, T, U, and Y (Lyczak et al., 2000).   
The first exotoxin that will be discussed is Exotoxin S.  Exotoxins S is a bifunctional 
cytotoxin that encodes an N-terminal Rho GTPase-activating protein domain and a C-terminal 
14-3-3-dependent ADP-ribosyltransferase domain (Pederson et al., 2000).  In culture, the Rho 
GAP domain stimulates actin reorganization.  The 14-3-3-dependent proteins influence cellular 
processes in eukaryotes by binding to specific phosphorylated sites on diverse target proteins and 
forcing a conformational change.  This action of the 14-3-3-dependent ADP-ribosyltransferase 
causes cell death (Pederson et al., 2000).  In continuing, the location of exotoxin S is key to its 
role in the pathogenicity of P. aeruginosa.  Located on the outer surface of the bacterium, 
exotoxin S serves as an adhesin.  Experimentation in the early nineties demonstrated that 
exotoxin S binds to the glycosphingolipid on the surface of the host cell (Baker et al., 1991).  
Additional evidence in support of the adhesin function of exotoxin S comes from research 
studying the exotoxin and its respective antibody.  When antibodies bind to exotoxin S and 
“block” its binding sites, inhibition of the attachment of P. aeruginosa to buccal cells of the host 
was seen (Baker et al., 1991).   
Exotoxin T, another exotoxin secreted by the TTSS, shares 75% amino acid identity with 
exotoxin S but only exerts 0.2% of its ADP-ribosyltransferase activity.  Very little is known 
about the role of exotoxin T in P. aeruginosa pathogenesis; however, recent work suggests a role 
in preventing uptake by epithelial cells (Hornef et al., 2000).   
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Figure 3. The Type III Secretion System of Pseudomonas aeruginosa.  A needle-like action is 
demonstrated as the exotoxins are injected directly from the bacterium inside the host cell.   
(http://webdepots.uma.es/gentica/tipoiii/Research.html) 
 
A third exotoxin, exotoxin U, is a 74-kDa protein that was initially identified by its 
cytotoxic activity towards mammalian cells.  It was found that some P. aeruginosa strains were 
capable of rapidly killing epithelial cells following co-cultivation in vitro.  This suggested an 
involvement of a cytotoxic factor which later became known as exotoxin U (Rabin et al., 2003).  
ExoU is found in about one-third of clinical P. aeruginosa isolates.  Ninety percent of these 
cases are associated with severe disease.  Intoxication with ExoU is associated with lung injury, 
bacterial dissemination, and sepsis in both animal and human infections (Phillips et al., 2003).  
In addition, it has been shown to cause fatality in a mouse model of lung infection.  Acquisition 
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of ExoU by P. aeruginosa strains lacking the type III effector protein increases the virulence of 
the strain as demonstrated in a mouse model of acute pneumonia.  Furthermore, septic shock, 
alveolar epithelial injury, and bacteremia are seen in a rabbit model of pneumonia when infected 
with the wild-type PA103, a P. aeruginosa strain possessing the exoU gene (Phillips et al., 
2003).  Little is known about the complete mode of action of the ExoU protein; however, studies 
have shown that deletions in the amino terminus or the carboxyl terminus eliminated the 
cytotoxic activity of ExoU.  In addition, studies have shown a central region of the protein to be 
significant in promoting virulence.  The current proposed model for ExoU interaction suggests 
that the amino and carboxyl termini of ExoU each bind to distinct eukaryotic factors.  The 
central region is used to bring these eukaryotic factors into close proximity eventually leading to 
cell death (Rabin et al., 2003).  Recent work identified a sequence similarity between the ExoU 
protein, mammalian phospholipase A2 (PLA2), and plant patatins.  An in vitro study 
demonstrated that the cytotoxic effects of ExoU were suppressed in yeast and mammalian cells 
by inhibitors against Ca2+ -sensitive cytosolic PLA2 (cPLA2) or Ca2+ -independent PLA2 
(iPLA2) (Pankhaniya et al., 2004).  This suggests that ExoU may have a function identical to 
plant patatins and PLA2 in catalyzing the cleavage of fatty acids from membrane lipids.  
Moreover, ExoU requires either a eukaryotic-specific modification or cofactor for its activity in 
vitro.  In continuing, ExoU is the first identified phospholipase virulence factor that is 
translocated into the cytosol by a TTSS (Sato et al., 2004).  As previously mentioned, some 
effectors of the TTSS require a chaperone for their secretion and translocation.  ExoU is one of 
the effectors that are associated with a chaperone.  Exotoxin U noncovalently binds to SpcU 
(specific Pseudomonas chaperone for exotoxin U).  This chaperone affects the extracellular 
levels and/or secretion of ExoU.  SpcU is predicted to weigh 14.9-kDa and have an acidic pI of 
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4.4 (Finck-Barbancon et al., 1998).  In addition, this exotoxin U chaperone has a conserved C-
terminal leucine motif.  Previously published data has suggested that SpcU may function by 
keeping ExoU from aggregating in the P. aeruginosa cytoplasm prior to secretion by the type III 
secretion system.  Furthermore, studies have indicated that in the absence of SpcU, small 
amounts of ExoU were detected in the supernatant.  This suggests that SpcU is not required for 
secretion or perhaps another chaperone substitutes for the SpcU function (Finck-Barbancon et 
al., 1998).  Finally, the last toxin secreted by the TTSS of P. aeruginosa is exotoxin Y.  Exotoxin 
Y is an adenylate cyclase whose amino-terminal region is not processed during secretion.  
Infection of eukaryotic cells with P. aeruginosa strains possessing the ExoY protein results in an 
elevation of intracellular cAMP and cell-morphology changes (Yahr et al., 1998).    
Another exotoxin secreted by P. aeruginosa is exotoxin A.  Unlike the previously 
discussed exotoxins, exotoxin A does not employ a type III secretion system.  Exotoxin A is 
delivered via the type II secretion system.  Utilizing this pathway enables the toxin to enter the 
host cells by receptor-mediated endocytosis rather than a direct injection into the host as is seen 
in the type III secretion system (Armstrong et al., 2004).  Exotoxin A consists of a single 
polypeptide chain of about 66 to 71-kDa.  It belongs to a family of enzymes known as mono-
(ADP-ribosyl) transferases and is an NAD+ -diphthamide ADP-ribosyl transferase.  The enzyme 
domain of exotoxin A catalyzes the transfer of ADP-ribose from NAD+ to the diphthamide 
residue in the eukaryotic translocation factor protein known as elongation factor-2 (Armstrong et 
al., 2004).  Elongation factor-2 functions in suppression of protein synthesis in the host cell 
causing cell death.  In addition, evidence for exotoxin A’s association with virulence is seen in a 
study that found the exotoxin present in sputum samples of patients infected with P. aeruginosa.  
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Furthermore, when administered intravenously at high doses, exotoxin A displays pro-
inflammatory activities (Wieland et al., 2002).   
 
 
VIRULENCE FACTOR
 
ACTIVITY
Lipopolysaccharide (LPS) Adhesion and Protects from Host Defenses 
Exotoxin U, S, T, Y Host Cell and Macrophage Apoptosis 
Exotoxin A  Suppress Protein Synthesis 
Phospholipase C & Rhamnolipid Solubilizes and Degrades Membrane 
Elastase Inhibits Monocyte Chemotaxis 
Alginate Inhibits Phagocytosis;  
Antimicrobial resistance 
 
Protease IV Degrades Host Proteins 
Quorum Sensing Cell-to-cell signaling 
Biofilm Protect from Host Defenses and Antibiotics 
Pili Twitching Motility and Adhesion 
 
Table 1. The Virulence Factors of Pseudomonas aeruginosa. 
 
3. Biofilms and Quorum Sensing Enhance Virulence 
 Another intriguing virulence factor of P. aeruginosa is the formation of a biofilm.  A 
biofilm is highly ordered microbial community enmeshed in a sculpted matrix.  The development 
of a biofilm is a process that involves both a quorum of cells and multicellular behavior.  A 
biofilm contains high numbers of organisms within a small scale.  Pathogen cell densities on a 
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surface can reach 1 x 107 cells/cm3 (Hassett et al., 2003).  In addition, a biofilm is an effective 
physical and metabolic barrier to antibiotic susceptibility and phagocytosis (Hassett et al., 2003).  
For this reason, the biofilm aids in the survival of the bacteria.  Recent studies have shown that 
the formation of P. aeruginosa biofilm on tissues of infected patients as well as on medical 
devices is responsible for the inherent resistance of the bacterium to certain antibiotics and other 
antimicrobial agents (Tielker et al., 2005).  Inside a biofilm, microorganisms can exist in a 
dynamic equilibrium where cell clusters form, mature, and detach to disseminate to new 
surfaces.  Furthermore, exopolysaccharides are considered essential components in biofilm 
formation determining its structural and functional integrity (Tielker et al., 2005).  Data 
published in the year 2005 has demonstrated a role of the lectin LecB in the development of P. 
aeruginosa biofilms (Tielker et al., 2005).  P. aeruginosa strains deficient in this lectin exhibited 
an impaired ability to produce biofilms.  Exhibiting the inability to properly form a biofilm 
would leave the bacterium susceptible to host immune defenses and would decrease the 
likelihood of survival.  Besides being unable to produce a biofilm, some bacteria have 
demonstrated awkward behavior in relation to the biofilm.  Bacteria have been observed 
detaching from the biofilm.  It has traditionally been thought that detachment from a biofilm is a 
passive behavior.  However, scientists are now entertaining the possibility of detachment as a 
strategy by which bacteria proactively colonize new niches before depleting the existing biofilm 
of space and nutrients (Hall-Stoodley et al., 2005).   
 Another virulence factor of P. aeruginosa that plays a significant role in its pathogenicity 
is quorum sensing.  Quorum sensing is the cell-to-cell signaling that controls the expression of 
many of the virulence factors making P. aeruginosa so dangerous.  Some extracellular virulence 
factors regulated by quorum sensing include elastase, alkaline protease, rhamnolipids, and lectins 
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(Chun et al., 2004).   In addition, quorum sensing is used during the formation of a biofilm.  This 
cell-to-cell communication is necessary in order to effectively employ the many virulence factors 
of the bacterium.  Evidence in support of this claim comes from studies showing that P. 
aeruginosa strains defective in its ability to partake in quorum sensing are inefficient in 
establishing a successful infection (Chun et al., 2004).  Quorum sensing in P. aeruginosa is 
mediated by the production, release and detection of acyl-homoserine lactones (acyl-HSLs).  P. 
aeruginosa produces two acyl-HSL signals: N-(3-oxododecanoyl)-L-homoserine lactone 
(3OC12-HSL) and N-butanoyl-L-homoserine lactone (C4-HSL).  These acyl-HSLs are 
hierarchically regulated in that threshold levels of 3OC12-HSL are required to activate C4-HSL 
production.  The two acyl-HSL signals regulate hundreds of genes in P. aeruginosa, control the 
production of a battery of extracellular virulence factors, and play a role in biofilm development 
(Chun et al., 2004).  In addition, P. aeruginosa produces a quinolone signal (PQS) known as 2-
heptyl-3-hydroxyl-4-quinolone.  PQS has been found in the lungs of cystic fibrosis patients 
infected by P. aeruginosa.  Although the exact role of PQS in quorum sensing is unresolved, it 
has been shown to be part of the P. aeruginosa quorum sensing hierarchy (McGrath et al., 2004).  
Furthermore, studies have shown that bacterial strains isolated from urinary catheters and contact 
lenses produce homoserine lactones when grown on agar plates.  This indicates the production of 
a biofilm to help in colonization.   
 Aforementioned, quorum sensing is needed for biofilm formation.  Studies have proven 
that the expression of quorum sensing genes can be detected in P. aeruginosa biofilms.  The 
expression of the quorum sensing genes lasI and rhlI is greatest at the base of the biofilm.  
Expression decreases as the height of the biofilm increases (Donabedian, 2002).  A reason for 
this may be the bacterial congestion experienced at the base of the biofilm.  Other recent work 
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has shown that P. aeruginosa’s tolerance to tobramycin, hydrogen peroxide, and 
polymorphonuclear leukocytes is quorum-sensing dependent.  In P. aeruginosa strains in which 
quorum sensing is deactivated by either a mutation or a quorum sensing inhibitory drug, the 
bacterium becomes susceptible to treatment with tobramycin and hydrogen peroxide.  In 
consequence, these bacteria are readily phagocytosed by PMNs (Bjarnsholt et al., 2005).   
4. The Flagellum – One of the Motility Devices Aiding in Virulence 
 The bacterial flagellum is the most common and best studied of all prokaryotic motility 
structures.  It is comprised of over 20 protein species with approximately another 30 proteins 
required for regulation and assembly.  Figure 4 provides an illustration of a typical flagellum.   
The flagellum is characterized as a rotary structure driven from a motor at the base with a 
filament acting as a propeller.  Its structure consists of three basic regions: the filament, the hook 
and the basal body (Bardy et al., 2003).  The filament consists of thousands of copies of a single 
protein known as flagellin and is about 20 nm in diameter.  The hook connects the filament to the 
basal body.  The basal body is comprised of a rod, a series of rings, the Mot proteins, the switch 
complex, and the flagellum-specific export apparatus.  The switch proteins allow the bacterium 
to switch rotation of the filament.  This action changes the direction of the swimming of the  
bacterium and usually takes place in response to attractants or repellents in the environment 
which are detected by the bacterial cell with a complex chemotaxis system (Bardy et al., 2003).  
In addition to motility, the flagellum is involved in modulation of adhesion to mucins, mediation 
of inflammatory responses, and a contributor to host cell invasion.  Over the years, studies have 
attempted to define the key players involved in flagellum function.  It has been shown that the 
FlhA component of the flagellum assembly apparatus has a primary role in bacterial 
internalization (Fleiszig et al., 2001).  Moreover, it has been determined that the flagellum 
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facilitates the acquisition of essential nutrients (Mahenthiralingam et al., 1995).  If the bacterium 
is in an area of the medium lacking nutrients, the flagellum is used to swim to another location in 
the medium where the nutrients are abundant.  Also, P. aeruginosa possessing flagella are more 
invasive than strains lacking this motility virulence factor (Mahenthiralingam et al., 1995).  
Amazingly, the flagellum of P. aeruginosa not only functions to benefit the bacterium but it also 
proves to be beneficial to the host.  Studies have determined that the presence of flagellum leads 
to the activation of the host immune defenses.  Finally, the flagellum seems to be a key factor in 
the stimulation of nonopsonic phagocytosis of the bacterium by macrophages and neutrophils 
(Mahenthiralingam et al., 1995).  These are two important molecules involved in an immune 
response. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The Flagellum.  The flagellum is a virulence factor involved in motility.  P. 
aeruginosa possesses polar flagella.  (http://courses.biology.utah.edu/temme/1000/list.html) 
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D. Pili of Pseudomonas aeruginosa – A Different Kind of Motility 
  1. Pilus Structure and Characterization 
  Pili are hair-like fibers extending out from the cell that allow the bacterium to interact 
with surfaces.  They are characterized as long polar, proteinaceous filaments composed of 
polymers of subunits termed pilin.  The pilin subunits of P. aeruginosa are arranged in a helical 
fashion on both poles of the bacterium (Paranchych et al., 1988).  Figure 5 provides a 
micrograph of P. aeruginosa demonstrating its polar pili.  Typically, pili are classified on the 
basis of the amino acid sequence of the pilin genes and their assembly mechanisms.  The amino 
acids comprising the primary structure of the P. aeruginosa pilin contain a short positively 
charged leader sequence.  The pilin sequence displays a highly conserved and highly 
hydrophobic amino-terminal domain (Mattick, 2002).  The C-terminus is amphipathic and 
encompasses a pair of cysteines that form a disulfide loop (Strom et al., 1993).  This type of pili 
is known as type IV pili.  The type IV pili are approximately 1-2.5 µm in length and 6 nm in 
diameter.   Depending on the species, type IV pilin is usually comprised of 145-160 amino acids 
(Mattick, 2002).  Furthermore, type IV pili are also referred to as the N-methylphenylalanine pili 
because they contain a methylated phenylalanine as the first amino acid of the processed pilin 
subunit (Hahn, 1997).  During processing of the pilin, the leader sequence is cleaved.  This 
results in an N-terminal residue that is methylated by a specific leader peptidase.  This peptidase 
is known as PilD.  In addition to P. aeruginosa, the pili of Dichelobacter nodosus, Neisseria 
gonorrhoeae, Neisseria meningitides, Moraxella bovis, Moraxella nonliquifaciens, Eikenella 
coorodens, and Vibrio cholerae are classified as type IV pili (Mattick, 2002).   
 The secondary structure of type IV pilin contains both α-helices and β-sheets.  Figure 6 
provides a representation of the secondary structure of the type IV pilin subunit.  The outside of 
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the fiber consists of a highly organized scaffold of β-sheets packed flat against the core.  The 
hydrophobic N-terminus tail of the pili is kept buried within the center of the filament (Keizer et 
al., 2001).  The C-terminal domain of pilin is embedded in a globular head domain (Mattick, 
2002).  Recent work focusing on electrostatic interactions between the globular domains of the 
pilin proteins and previous X-ray diffraction data have predicted that the coiled N-terminus of 
each subunit complement each other (Keizer et al., 2001).  Moreover, it was determined that 
these pilin subunits are offset such that they wind around in a helical fashion with a left-handed 
twist.  These hydrophobic N-terminal helices associate to form 5-helix bundles with Glu5 
interacting with the basic surface on the inside of the pilus globular portion (Keizer et al., 2001).  
Furthermore, X-ray diffraction data suggested that the outer diameter of the pilus is 
approximately 52 Ǻ and the inner diameter is represented as a 12 Ǻ “hole” in the center of the 
pilus.  This small hole possess problems to DNA or RNA that might want to pass through the 
center of the pilus (Keizer et al., 2001).   
        2. Pilus Synthesis, Assembly, and Regulation 
Synthesis of type IV pili is elaborate and requires the involvement of at least 35 genes (Ishimoto 
et al., 1989).  PilA is the structural pilin protein.  PilA is transcriptionally regulated by the σ54 
subunit of RNA polymerase encoded by rpoN.  Mutants lacking a functional rpoN gene do not 
produce pili unless complemented with a plasmid containing the pilA gene behind an active 
promoter (Ramphal et al., 1991).  Two positive regulators of pilA transcription, pilR and pilS, are 
involved in a two-component signaling pathway controlling expression of pilA (Strom et al., 
1993).  pilR encodes a transcriptional activator.  pilS is a sensor kinase involved in a signal 
transduction mechanism responsible for initiating pilin synthesis (Strom et al., 1993).  Upstream 
of pilA is a region containing the genes pilB, pilC, and pilD.  PilB is a nucleotide-binding 
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protein.  It is believed to be located in the cytoplasm or associated with the cytoplasmic 
membrane.  In addition, PilB may also supply energy required for pilin translocation or 
assembly.  Little is known about PilC; however, it is known to be an integral membrane protein 
(Mattick et al., 1996).  The roles pilB and pilC play in pilus assembly can be seen in mutants 
lacking either of these genes.  When pilB and pilC are absent from the genome, a buildup of 
mature pilin subunits is seen in the cytoplasmic membrane (Strom et al., 1993).  PilD has a dual 
function in the biosynthesis of the type IV pili of P. aeruginosa.  First, this enzyme is responsible 
for N-terminal processing of the prepilin.  Encoded by the pilA gene, PilA is initially synthesized 
as a prepilin with a six amino acid leader peptide.  This leader peptide proceeds to be cleaved by 
PilD.  Secondly, PilD is the enzyme that methylates the N-terminal amino acid of the mature 
protein (Alm et al.,1997).   PilQ, another protein involved in pili biosynthesis, is a multimeric 
outer membrane protein.  It belongs to a family of proteins that form gated pores in the outer 
membrane of the bacterium.  It is through this hole that the pilus is thought to extrude (Mattick, 
2002).  Electron microscopy has shown that PilQ forms a dodecameric doughnut-shaped 
complex whose internal cavity diameter closely matches the diameter of the corresponding pilus 
(Mattick, 2002).  Additionally, due to its homology to cell division proteins, PilM has been 
proposed to direct the location of piliation to the cell poles (Mattick, 2002).  Furthermore, PilT 
and PilU are proteins responsible for the motility of P. aeruginosa (Mattick, 2002).  These 
proteins are involved in the retraction of the pilus that in turn enables the bacterium to be motile.  
These two proteins will be discussed in detail in the following section.  Finally, prepilin-like 
proteins have been identified.  PilE, PilV, FimT and FimU all resemble prepilin and are 
processed by PilD.  The functions of these proteins are still unknown; however, studies analyzing 
strains mutant in PilE, PilV, and FimU result in nonpiliated cells (Bardy et al., 2003)  
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 Flagellum 
Bundles of Pili 
 
 
 
Figure 5. Electron Micrograph 
Illustrating the Pili of 
Pseudomonas aeruginosa 1244.  
Note the bundles of pili located at 
the poles (Jewell, 2004). 
 
 
 
 
 
 
 
 
           
  
 
 
 
 
 
 
 Figure 6. The Pilin Subunit.  The 
secondary structure of the type IV pili of 
P. aeruginosa contains both α-helices and 
β-sheets.  The location of the disulfide 
loop that is characteristic of type IV pili 
is emphasized with a box enclosing the 
loop (Hazes et al., 2000). 
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   3. Pilus Function 
 
 Type IV pili play a plethora of significant roles in contributing to the pathogenicity of P. 
aeruginosa.  A primary function of the pili is twitching motility.  Twitching usually involves 
cell-to-cell contact (Mattick, 2002).  Most often, the contact involves the pili of the bacterium 
with host tissue.  This motility occurs from a sequence of retracting and extending of the pili.  
Extension results from the polymerization of pilin subunits.  Retraction is a consequence of 
depolymerization of the pilin subunits.  This allows the pathogenic bacteria to attach to the host 
tissue and draw themselves throughout the host.  In P. aeruginosa, the retraction/extension 
motility is enabled by the retracting action of PilT and PilU.  These are proteins with putative 
nucleotide-binding domains.  Studies have shown that mutants in pilT and pilU of P. aeruginosa 
have reduced cytotoxic activity in various types of epithelial cells in vitro (Zolfaghar et al., 
2003).  Although each mutant was still virulent in the lung environment, strains lacking these pili 
retraction genes were unable to disseminate from the lung to the liver.  This suggests that 
twitching motility involving the extension and retraction of pili is essential to bacterial motility 
enhancing the pathogenesis of P. aeruginosa.  Other studies have shown nonpiliated strains of P. 
aeruginosa to be less virulent in lung infection models than piliated strains (Comolli et al., 
1999).   This provides further evidence suggesting an essential role for the pili in P. aeruginosa 
pathogenesis.  Furthermore, studies conducted in 2001 resulted in a direct observation of 
extension and retraction of type IV pili (Skerker et al., 2001).  When the distal tip of a filament 
was attached to a quartz surface, it was pulled straight.  Once the tip was released, the filament 
was able to retract.  This resulted in the cell body moving forward- the phenomenon of twitching 
motility (Skerker et al., 2001).  Another study conducted in 2000 utilized laser tweezers to 
demonstrate the retractile properties of the type IV pili (Merz et al., 2000).  When laser tweezers 
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were used to place and hold cells near a microcolony, retractile forces pulled the cells near the 
microcolony.  To quantitate this observation, the type IV pili of immobilized bacteria were 
bound to a latex bead.  The pili retracted pulling the bead away from the tweezers that were used 
to secure the bead.  The beads were pulled at forces exceeding 80 pN (Merz et al., 2000).  
Additional studies conducted in 2002 demonstrated that a single pilus fiber was responsible for 
retraction events.  Moreover, it was found that only one PilT complex powers retraction (Maier 
et al., 2002).   
 The type IV pili function as an adhesin binding to a variety of surfaces including inert 
surfaces, other bacterial cells, and eukaryotic cells.  By binding, the pili mediate both 
colonization of the surface and intimate contact between the bacterium and the host cell through 
pili retraction (Merz et al., 2000).  In P. aeruginosa, the pili bind to the host cell’s asialo GM1 
gangliosides.  P. aeruginosa creates an enhanced receptor for the pili by producing a 
neuraminidase to remove the sialic acid residues from the GM1 to form asialo GM1 (Salyers et 
al., 2002).  Monoclonal antibodies specific for defined regions of the pilin monomer, purified 
pili, and synthetic peptides corresponding to specific peptide sequences within the pilin subunit 
inhibited bacterial attachment to buccal and tracheal epithelial cells (Strom et al., 1993).  In 
addition to acting as an adhesin, the pili are also responsible for the formation of microcolonies.  
The type IV pili tend to aggregate.  This in turn leads to “autoagglutination or autoaggregation” 
in vivo.  The result is a three-dimensional microcolony on the target tissue.  The bacterial cells 
use this microcolony as a form of protection from the host immune system (Craig et al., 2004).  
The pili also function to enable the bacteria to seek and locate appropriate target cells or find a 
weak area within a tissue for effective penetration and invasion (Shi et al., 2002).  Finally, the 
pili of P. aeruginosa may function as the targets recognized by phagocytic cells (Strom et al., 
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1993).  Studies have demonstrated that the pili of P. aeruginosa were required for nonopsonic 
phagocytosis by human neutrophils and monocyte-derived macrophages (Speert et al., 1986).  
Without the pili, components of the host immune system are not able to properly recognize the 
bacteria and proceed with phagocytosis.   
 4. Glycosylation of Pili 
 The glycosylation of prokaryotic proteins was thought to be a very uncommon 
occurrence in the scientific world; however, in 1974, experiments were conducted proving that 
the S-layer of the archaea Halobacterium halobium were glycosylated (Mescher et al., 1974).  
Up until recently, protein glycosylation in bacteria has been associated with the S-layer.  In 1995, 
the pili of P. aeruginosa strain 1244 were found to be glycosylated by the presence of pilO 
(Castric, 1995).  pilO encodes a 50.9-kDa protein, PilO, which allows for the addition of an 
acidic carbohydrate moiety to the pilin structural protein.  As seen in Figure 7, the pilO gene is 
located directly downstream of pilA and directly upstream of tRNAthr gene on the group I operon.  
The group II operon does not contain the pilO gene and therefore produces non-glycosylated pili.  
In order to verify the role of PilO in pilus glycosylation, mutants were created in which the pilO 
gene was removed.  This resulted in an unmodified or an nonglycosylated strain of P. aeruginosa 
(DiGiandomenico et al., 2002).   
 The primary structure of PilO contains nine hydrophobic regions that are flanked by 
clusters of charged residues.  These positively charged flanking residues may play a role in the 
stabilization of the structure through ionic interaction with membrane phospholipids (Castric 
1995).  Moreover, it has been suggested that polar residues promote a surface solvent interaction 
on both sides of a membrane.  Additionally, a significant alteration in pilin charge is seen with 
the presence of pilO.  Studies have shown that pilin produced by strains carrying the active pilO 
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gene, 1244N3(pPAC46) (rpoN-pilO+ mutant rescued by the plasmid PAC46 carrying the rpoN 
gene) and the wild-type strain 1244 (rpoN+pilO+), has a pI of 4.75.  Strains such as 
1244N3(pPAC24) (rpoN- with no rescue), which lack the active pilO gene, have a pI of 6.25 
(Castric, 1995).   
 Furthermore, recent work has shown that the glycan resulting from the glycosylation of 
the pili is a trisaccharide.  The glycan consists of α-5NβOHC47NfmPse-(2Æ4)-β-FucNAc which 
is attached between a serine β carbon and the C-1 of FucNAc via an O linkage (Castric et al.,  
2001).  Figure 8 illustrates the P. aeruginosa 1244 pilin aminoglycan structure.  Work published 
in 2002 identified the pilin glycan of P. aeruginosa 1244 pilin to be attached to serine 148, the 
carboxy-terminal residue of the pilin protein (Comer et al., 2002).  The glycan has also been 
shown to be in close proximity to the pilin disulfide loop (DSL).  The disulfide loop is an 
important structure in pilus adhesion (Comer et al., 2002).  It serves as the pilus receptor for host 
cell glycolipid recognition.  Research has shown that the pilin glycan of P. aeruginosa is a 
product of the O-antigen biosynthetic pathway.  Mutants of wbpL and wbpM, genes involved in 
the initial steps of O-antigen biosynthesis, were concocted to determine if a similarity existed 
between the O-antigen and the pilin glycan.  After western blot analysis, the pilin of both 
mutants had a molecular weight that was consistent with that of non-glycosylated pilin 
(DiGiandomenico et al., 2002).  This indicated that both the glycan and the O-antigen utilized 
similar synthesis pathways.  Moreover, it was determined that the mechanism of glycosylation in 
P. aeruginosa 1244 has broad specificity.  Studies utilizing cloned O-antigen biosynthesis gene 
clusters from PA103 (LPS serotype 011) in PA1244 (LPS serotype 07) resulted in a P. 
aeruginosa strain possessing both 07 and 011 antigens (DiGiandomenico et al.,  2002).   
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Figure 7. Schematic of Group I and Group II Operons.  pilA is the structural gene.  pilO is 
the gene encoding for pilin glycosylation.  tRNAThr is an anticodon.  P. aeruginosa 1244 has the 
group I operon. 
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Figure 8. The P. aeruginosa 1244 Pilin Aminoglycan Structure  (α-5NβOHC47NfmPse-  
(2Æ4)-β-FucNAc) (Castric et al., 2001). 
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5. Role of the Pilin Glycan in Pathogenesis 
 Many researchers have attempted to determine the exact role of the pilin glycan.  Recent 
studies have suggested that carbohydrate modifications on proteins can play a role in adhesion, 
protection against proteolytic cleavage, solubility, antigenic variation, and protective immunity 
(Szymanski et al., 2002).  In N. meningitidis, a Gram-negative bacterium, glycosylated pili have 
been shown to protect the bacterium from complement binding which could lead to protection 
against phagocytosis (Virji et al., 1993).  Another study conducted on Campylobacter and N. 
meningitidis suggested that the pilin glycan protects potential epitopes from the host B-cell 
response (Szymanski et al., 1999).  Additionally, studies have demonstrated that the loss of the 
carbohydrate components from glycoproteins causes a drastic reduction in reactivity (Szymanski 
et al., 1999).  This suggests that the glycosyl moieties may be immunodominant and very little, if 
any, antibody is produced against the amino acid components.  Moreover, recent experiments 
have demonstrated that the pilin glycan is distributed evenly over the pilus (Jewell, 2004).  Since 
the glycan is located over the entire surface of the pilus, it is highly concentrated.  It may be 
possible that the glycan serves as a mask for the pilus-binding site.  The glycan may block the 
binding sites along the pilus hindering the opportunity for any antibodies or other components of 
the immune system to bind.  This would promote the survival of the bacterium since the initial 
response of the immune system is to produce antibodies to aide in neutralization of the bacteria.  
Without the challenge of the immune system, the bacteria can continue to cause infection inside 
the host.   
 6. Glycosylated Pili as a Vaccine Candidate 
 Studies of immunity to P. aeruginosa have demonstrated that a variety of potential 
immunogens can elicit protection utilizing both antibody and cell-mediated immune effectors.  
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Earlier research has shown that the pili of P. aeruginosa strain 1244 are able to stimulate glycan-
specific antibodies (Comer et al., 2002).  Moreover, it was demonstrated that the antibodies 
specific for the 1244 pilin glycan are also able to recognize the LPS from P. aeruginosa (Comer 
et al., 2002).  These incredible findings open up the field of P. aeruginosa vaccine studies, as 
well as some other Gram-negative bacteria, enabling researchers to raise a protective-LPS 
specific T-dependent B-cell response without the disadvantages of LPS toxicity 
(DiGiandomenico et al., 2002).  Furthermore, studies have shown the use of purified pili 
antiserum as a vaccine decreased the adherence of the homologous P. aeruginosa strain in vitro 
(Stanislavsky et al., 1997).  The use of heterologous, or unpurified, pili as a vaccine did not 
decrease adherence of the bacterium.  This suggests that the pili are an optimal structure to target 
due to their role in the virulence of P. aeruginosa.  As to the particulars of the vaccine, it has 
been determined that the N-terminus is not a good candidate (Stanislavsky et al., 1997).  Firstly, 
most immunogenic regions are hydrophilic.  The N-terminus of P. aeruginosa pili is 
hydrophobic.  Secondly, it may not be accessible for antibodies to interact with it (Stanislavsky 
et al., 1997).  Aforementioned, the N-terminus is buried in the pilus restricting access by 
antibodies.   
 E. Thesis Goals 
 The ultimate goal of this thesis will be to determine if the pilin glycan plays a role in the 
pathogenicity of Pseudomonas aeruginosa 1244.  I will utilize a murine model of acute 
pneumonia to establish if there is a difference in virulence based on the presence of glycosylated 
pili.  Furthermore, work will be conducted to determine if the pilin glycan aids in virulence by 
inhibiting nonopsonic phagocytosis by polymorphonuclear leukocytes (PMN’s). 
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 Firstly, I will manipulate a strain of P. aeruginosa that will allow for the optimal 
experimental conditions.  Previous work has shown that the presence of the type III effector 
protein ExoU increases the virulence of a bacterial strain by lowering the LD50 value (Allewelt et 
al., 2000).  I will utilize this information and allow for the acquisition of ExoU by P. aeruginosa 
1244.  Once I have confirmed that PA1244 has acquired the exoU gene, I will proceed with 
animal experimentation to verify that ExoU does indeed lower the LD50 value. 
Secondly, I will perform a competition assay.  I will utilize two variants of a P. 
aeruginosa strain carrying exoU.  The first strain will possess glycosylated pili, strain 
(1244(pUCP19exoUspcU), and the second strain will possess non-glycosylated pili, strain 
(1244G7pUCP19exoUspcU).  Female mice will be administered equal amounts of both bacteria 
in order to determine which strain will colonize more effectively.  After removing selected 
organs and plating the homogenates, I will be able to determine if the pilin glycan provided a 
selective advantage to the survival of P.aeruginosa.  
Lastly, in an attempt to determine how the pilin glycan aids in virulence, I will utilize the 
same two P. aeruginosa strains but without the exoU gene in a nonopsonic phagocytosis assay.  
Previous research has suggested that pili generate a net hydrophobic force that enhances the 
interaction between polymorphonuclear leukocytes (PMN’s) and the bacterium (Speert et al., 
1986).  This attraction has been shown to take place without the assistance of other components 
of the host immune system such as serum (Speert et al., 1984).  I intend to determine if the pilin 
glycan associated with the wild-type P. aeruginosa 1244 disrupts this attractive force and 
prevents phagocytosis mediated by human PMN’s.  
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II. Material and Methods  
A. Bacterial Strains 
 Table 2 encompasses a list of all bacterial strains and plasmids that were utilized in this 
research.  A concise description of each bacterial strain, along with any selective markers, is 
included. 
Table 2. Bacterial Strains, Plasmids, and Selective Markers 
                                                                                                                                                      i
    Bacterial                             Description                         Selective                    Reference 
      Strain                                                                             Marker1                                            e                          
 P. aeruginosa 1244         Wild-type; produces                None              Castric et al., 1989 
      glycosylated pili; 
                                            serogroup O7  
 
P. aeruginosa 1244G7     PilO- mutant; produces            Gm100             Smedley et al., 2001 
                                                 non-glycosylated pili 
   
P. aeruginosa 1244-47        PilA- and PilO- mutant;           Hg100                    Castric, unpublished 
                                                      absence of pili 
 
P. aeruginosa 01                  Type II non-glycosylated       None               Holloway, 1955                                  
                                                 pili; ExoU-
 
P. aeruginosa 103                 Type II non-glycosylated        None               Liu, 1966 
                                                          pili; ExoU+ 
 
P. aeruginosa wbpL               Non-glycosylated pili;            Gm300             DiGiandomenico 
                                                       no O-antigen                                                et al., 2002 
 
E. coli HB101                         Highly transformable;             None               Sambrook et al., 
                                                      no O-antigen                                                     1989 
________________________ ____________________________________________________ 
    Plasmid                               Description                         Selective                    Reference 
______________________________________________ Marker_______________________ 
pUCP19exoUspcU                Plasmid carrying                     Cb250               Finck-Barbancon              
                                                  TTSS protein                                                     et al., 1998    
                                                 with chaperone                                    
____________________________________________________________________________
1 Abbreviation key: Cb= Carbenicillin Disodium Salt, Gm=Gentamicin Sulfate, Hg=Mercury.  
Antibiotic concentrations listed throughout are in µg/ml. 
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B. Cell Growth Conditions 
 All cultures were grown in LB (Luria Bertani) broth or on TSA (trypticase soy agar), NA 
(nutrient agar), or LB plates.  Incubation times for each culture ranged from 10 to 14 hours at 
37°C or 30°C.  All broth cultures were agitated (250 rpm) during the incubation process.  
Antibiotic conditions required for each plasmid construct are listed in Table 2. 
C. DNA Techniques 
1. Plasmid Purification  
A single colony from both PAO1(pUCP19) and PAO1(pUCP19exoUspcU) strains grown 
on LB Cb250 plates was used to inoculate an overnight broth culture.  One and a half milliliters 
was removed from each overnight and transferred to a 1.5 ml eppendorf tube.  The pUCP19 
plasmid with and without the exoU gene and its chaperone spcU was purified using a 
Stratagene StrataPrep Plasmid Miniprep Kit (La Jolla, CA).   
2. Agarose Gel Electrophoresis 
The results of the plasmid extraction, the bacterial transformation, the restriction digest, 
the quantitation of plasmid DNA, and the PCR were confirmed via DNA agarose gel 
electrophoresis.  Each sample was prepared in 6X loading buffer as described by Sambrook 
(1989).  Prior to loading the gel, each sample was placed in a microcentrifuge (~1400 rpm) for 
approximately 10 seconds.  The mini-gel apparatus utilized in the electrophoresis was supplied 
by International Biotechnologies, Inc. (New Haven, CT).  The gel was comprised of 0.8% 
agarose and 0.5 µg/ml ethidium bromide (EtBr).  The running buffer used was 1X TBE buffer 
(89 mM tris, 89 mM boric acid, 2 mM EDTA, pH 8.3) with the addition of 0.25 µg/ml of EtBr. 
The gel was run at a constant voltage of 100 V for approximately 40 minutes.  A λ HindIII digest 
manufactured by New England Biolabs, Inc. (Beverly, MA) was used as the molecular weight 
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standard.  Once completed, the gel was viewed by means of a Spectroline Model TR-302 UV 
transilluminator and an image was captured using a Fotodyne Incorporated Polaroid Camera 
(Hartland, WI).   
 For situations in which it was necessary to quantitate DNA, an agarose gel 
electrophoresis was conducted by running the sample DNA in conjunction with varying amounts 
(100 ng, 50 ng, and 25 ng) of λ phage DNA.  After EtBr staining, the intensity of each band was 
compared to that of the λ phage DNA band and an estimation of the concentration of the DNA 
was made.  Bands on the PCR agarose gel were visualized using Molecular Dynamics Fluor 
Imager 595 (Sunnydale, CA).  The finished gel product was placed in an imaging processor that 
scans the gel.  This scan is then projected on a computer screen.  The image can then be 
manipulated to normalize each band according to the intensity of the background.  
 3. Electroporation 
The plasmid pUCP19exoUspcU was electroporated into P. aeruginosa strains 1244, 
1244G7, and 1244-47.  Overnight broth cultures were prepared from a frozen stock of cells 
maintained in 15% glycerol at -80 oC.  Using a Bausch & Lomb Spectronic 70 (Rochester, NY), 
the optical density of each overnight culture was adjusted to contain approximately  
4.98 x 108 cells/ml at a wavelength of 540 nm.  Fifteen and a half milliliters of each culture was 
removed and centrifuged (7000 g/10 minutes/4ºC/SS-34 Sorvall rotor).  The supernatant was 
discarded and the pellet was suspended in 15.5 ml of 300 mM sucrose.  The centrifugation was 
repeated and the pellet was once again resuspended in 15.5 ml of 300 mM sucrose.  The 
suspension was subjected to a final centrifugation and was resuspended in 100 µl of 300 mM 
sucrose.  This resulted in a final concentration of 1x1011 cells/ml.  In order to prepare the cells 
for the electroporation, the cells were incubated on ice for 30 minutes.  Meanwhile, electro-
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cuvettes needed for the electroporation were pre-chilled on ice.  Once the cuvette was chilled and 
the cells were made electrocompetent, 5 µl of the appropriate plasmid DNA was added to 40 µl 
of the corresponding electrocompetent cells.  Each cuvette was cleaned with a Kimwipe to 
remove any unwanted moisture and placed in the Bio-Rad gene pulser (Hercules, CA).  The 
length of time for the electroporation varied by strain taking 4.6 seconds for strain 
1244(pUCP19) and 4.5 seconds for all the other strains.  The voltage for the procedure was 1600 
V, the capacity was 25 µFD, and the resistance was 200 Ohms.  Once electroporated, 1 ml of LB 
broth was added to the cuvette containing the cells.  The sample was mixed by gentle aspirations 
with a pipette and transferred to a 25 ml sterile flask containing 2 ml of LB broth.  The cultures 
were incubated at 37oC with agitation (250 rpm) for approximately 2 hours.   
A transformation efficiency was calculated by dividing the average number of 
transformants by the micrograms of plasmid DNA used in each sample.  It was determined that 
0.375 µg of pUCP19 DNA and 1 µg of pUCP19exoUspcU DNA was present in each sample.  In 
order to enumerate transformants, bacterial cells that have undergone electroporation were plated 
onto LB Cb300 plates.   Using a hockey stick to employ the spread plate technique, 200 µl and 
400 µl of each strain was plated and placed in a 37°C incubator for approximately 12 hours.  
Because the pUCP19exoUspcU plasmid contained a carbenicillin resistance gene, all media 
contained carbenicillin to restrict growth to those strains transformed with the pUCP19 plasmid.  
The average number of transformants/µg plasmid DNA was calculated for each strain. 
Since the plasmid utilized in the electroporation contained an EcoR1 and a HindIII 
restriction site, a digestion could be employed to verify the presence of the plasmid in the 
selected Pseudomonas aeruginosa strains.  In order to purify each transformant, a dilution streak 
was prepared on LB Cb250 plates and grown overnight.  The broth cultures were grown up for 12-
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14 hours at 37oC with agitation (250rpm).  Plasmid DNA was extracted from each strain using a 
Stratagene StrataPrep Plasmid Miniprep Kit (La Jolla, CA).  Two extractions were made for each 
bacterial strain to ensure efficiency.  A restriction digest comprised of 500 ng of plasmid DNA, 
20 units of EcoRI (New England Biolabs, Inc.; Beverly, MA), 10 units of HindIII (New England 
Biolabs, Inc.; Beverly, MA), and 2 µl of Buffer 2 brought up to a total volume of 20 µl in 
deionized water was allowed to proceed for 2 hours in a 37oC waterbath. 
   4. Identification of the exoU Gene 
 In order to confirm the absence of the exoU gene from the wild-type P. aeruginosa 1244, 
chromosomal DNA was analyzed via Polymerase Chain Reaction (PCR).  Chromosomal DNA 
was extracted from an overnight broth culture by using a QIAamp DNA Mini Kit produced by 
Qiagen (Valencia, CA).   
DNA amplification was conducted by utilizing primers 5’-GGGAATACTTTCCGGGAA 
GTT-3’ (880 ng/µl) and 5’-CGATCTCGCTGCTAATGTGTT-3’ (1000 ng/µl) that were 
developed from a conserved region of DNA (Allewelt et al., 2000).  DNA was amplified from 
the purified chromosomal DNA using the Eppendorf Mastercycler Gradient Thermal Cycler 
manufactured by Brinkman Instruments, Inc. (Westbury, NY).  Each reaction was performed in a 
total volume of 50 µl and consisted of 1 mM dNTP, 120 ng of each primer, 5 Units of Taq 
polymerase (New England Biolabs, Inc.), 5 µl of 10X Taq Buffer (New England Biolabs, Inc.), 
and between 3-8 ng of template DNA (8 ng of PA1244, 4 ng of PA103, and 3 ng of PA01) 
brought up to 50 µl with deionized water.  The PCR cycles were performed as follows: initial 
step of 94oC for 5 minutes, 36 cycles of several steps (94 oC for 1 minute, 53 oC for 1 minute, 72 
oC for 1.5 minutes), a final step of 72oC for 7 minutes, and an overnight hold of 4oC.  The PCR 
was confirmed via two 0.8 % DNA agarose gels containing either Vistra Green Dye (1 µl/10 ml) 
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manufactured by Amersham Biosciences (Piscataway, NJ) or ethidium bromide, as previously 
described, and analyzed using the Molecular Dynamics Fluor Imager 595.   
  D. Animal Experimentation 
1. Murine Model of Acute Pneumonia  
All animal work was completed in compliance with the federal regulations of the 
Institutional Animal Care and Use Committee (IACUC).  Six to eight week old female balb/c 
mice (60-80 mg) were purchased from Hilltop Laboratories (Scottsdale, PA) and utilized for all 
animal experimentation.  Female mice were preferred because they are less aggressive than male 
mice.  After arriving at Duquesne University’s animal facility, each mouse was given 
approximately 3 days to acclimate to the new environment prior to experimentation.  Each set of 
experiments contained a different total number of mice; however, each test group was always 
comprised of either 3 or 4 mice.  Henceforth, each cage contained 3-4 mice that were given an 
identical concentration of inoculum.  On occasion, the mice were divided and 2 mice inhabited a 
single cage.  Having fewer mice in one cage prevents the chance of death due to fighting 
amongst the mice.   
The model organism utilized in this work is known as the respiratory mouse model of acute 
pneumonia.  This model is preferred for the desired research because of the mouse response 
while under the effects of the anesthesia.  While anesthetized, the mouse begins to 
hyperventilate.  This leads to an ideal situation in which the inoculum can be administered 
directly to the nare and the mouse will inhale it during the hyperventilation process.  In addition, 
the respiratory mouse model is a good model organism to utilize in this study because the mouse 
does not have a gag reflex; therefore, the mouse will get the entire dosage administered to her 
and not cough it up.  Finally, the acute pneumonia model is used because of the frequency of P. 
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aeruginosa infections associated with the lungs, specifically in cystic fibrosis patients.  Because 
of its common occurrence in the lung and the ease of intranasal administration, it is practical to 
use such a model.  
The anesthesia consisted of a ketamine (provided by Duquesne University Animal Facility; 
Pittsburgh, PA) /xylazine (manufactured by Sigma; St. Louis, MO) mixture.  Twenty milligrams 
of xylazine was added to 1 ml of ketamine.  This solution was placed on a Fisher Scientific 
magnetic stirrer (Pittsburgh, PA) and mixed.  After the xylazine has gone into solution, the 
mixture was brought up to 15 ml with saline.  The solution was then filter sterilized (25 mm 
syringe filter) and placed in a sterile 15 ml tube.  Each mouse was administered 0.25 cc  
(5-10 mg/kg mouse) of the anesthesia via the intraperitoneal cavity.  After waiting approximately 
one to two minutes, the feet of each mouse were gently pinched to determine if the mouse was 
completely under the anesthesia.  If the mouse does not flinch or respond to the gentle pinch, the 
mouse is completely under the effects of the anesthesia.  If the mouse moves when a gentle pinch 
is applied to the paw, a few more minutes must first pass before conducting any experimentation 
on that particular mouse.  The ketamine/xylazine anesthesia allows the mice to regain 
consciousness within a few hours. 
Once the mouse was unresponsive to touch, either 10 µl of sterile PBS or 10 µl of the 
inoculum was administered to each nostril.  This resulted in each mouse receiving 20 µl of the 
desired substance.  During administration, the mouse was held securely in the hands and was 
kept in an upright position.  The tip of the pipette was stationed near the nare and the inoculum 
was gently administered in accordance with the inhalation rhythm of the mouse.  After 
completing the inoculation, the mice were carefully placed on their backs inside of their cages.  
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The mice awoke in a few hours and proceeded with their normal activities as the bacteria began 
to infect their body. 
2.  Determination of LD50
As a general means of testing the virulence of one strain in relation to another, the 50% 
lethal dose was calculated for several P. aeruginosa strains.  It is practical to use a fifty-percent 
endpoint due to the fact that this endpoint would be less affected by small chance variations than 
any other endpoint (Reed et al., 1938).  Therefore, this value would be the most reliable 
numerical assessment of virulence in a bacterial strain.  In addition, the LD50 value can be used 
to evaluate a change in virulence based on the acquisition of a certain gene.  In this work, both 
long term and short-term LD50 studies were performed.  The long-term studies were conducted 
over a time period of three weeks.  P. aeruginosa 1244-47(pUCP19exoUspcU) was the only 
strain utilized in the long-term LD50 studies.  The short-term studies were conducted on all three 
P. aeruginosa strains possessing the exoU gene over a time period of three days.  All bacterial 
strains used in the LD50 studies were grown on TSA Cb250 plates for 12 hours at 37ºC.  In order 
to harvest the cells, a sterile swab was used to gently scrap the cells from the plate.  The swab 
was then swirled around in a sterile tube containing approximately 8 ml of sterile PBS (0.8% 
NaCl, 0.02% KCl, 0.06% Na2HPO4, 0.02% KH2 PO4, bring up in 1 liter deionized water, pH to 
7.3).  The optical density was normalized by adjusting the absorbance at a wavelength of 650 nm 
to approximately 0.500.  Once the density was adjusted, each strain was diluted in sterile PBS to 
get the desired inoculum.  The desired inocula for each strain in the LD50 study can be found in 
Table 3.  Table 4 encompasses a list of the desired inocula utilized in the short-term LD50 study.  
Unfortunately, the desired concentration of the inoculum is only an estimation and is often 
different from the concentration of the inoculum that was administered.  In order to determine 
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the exact amount of bacteria given to the mice, ten-fold serial dilutions of each inoculum were 
made in NB (nutrient broth) on the day of the experiment.  Ten microliters of each dilution was 
plated in duplicate onto NA Cb250 plates using the drop dilution technique.  Plates were allowed 
to incubate for approximately 24 hours at 30ºC.  Colonies were counted and actual inoculum 
concentrations were determined.     Table 5 provides the week-by-week protocol for the long-
term LD50 study while Table 6 provides the protocol for the short-term LD50 study.   
In order to calculate the lethal dose needed to infect and destroy half of the experimental 
population for each strain, the equation used by Reed and Muench in 1938 was employed (Reed 
et al., 1938).  Table 7 provides an example of survival data used to calculate an LD50 value.  The 
number of mice surviving and succumbing to each inoculum dosage was used to determine a 
percent mortality for each inoculum.  Column (a) in Table 7 demonstrates the inoculum density 
given to a certain group of mice.  Columns (b) and (c) provide the live/dead analysis for the mice 
at a particular inoculum density.  Columns (d) and (e) provide the total live/dead analysis for the 
overall experiment.  It is assumed that a mouse surviving at a given inoculum density would 
have survived at a lower inoculum density.  Column (b) is therefore added from the bottom and 
the subtotal from each inoculum density is entered in column (d) as the accumulated number of 
mice surviving at this plus lower inoculum densities.  Conversely, a mouse dead at a given 
inoculum density would have died at any higher inoculum density.  Column (c) is added from the 
top and the subtotals in column (e) give the cumulative numbers of mice dying at a given 
inoculum density plus higher densities.  Percent mortality was calculated from columns (d) and 
(e).  For example, of a total of 4 mice administered an inoculum density of 3.1 x 105, zero mice 
survived at this or a higher inoculum while four mice died at this or a lower inoculum.  The 
calculated mortality rate is therefore 100%.   
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From here, the percent morality values were used to estimate an LD50 value by finding 
the inocula with the percent mortality values closest to 50%.   In Table 7, it is estimated that the 
LD50 value is between an inoculum density of 1 x 105 and 3.1 x 105.  A proportionate distance 
value was determined by taking the percent mortality of the inoculum density below the 
estimated 50% mortality and subtracting it from 50%.  This value is then divided by the percent 
mortality above the estimated 50% mortality value subtracted by the percent mortality below the 
estimated 50% mortality value ((50 % - 0 %) / (100 % - 0 %)). 
Since the dilutions are increasing on a logarithmic scale, it is necessary to factor in the 
log of the inoculum densities.  The log of the lower inoculum density closest to the estimated 
50% mortality value is calculated (log (1 x 105)).  Next, the log of the result of the higher 
inoculum density closest to 50% mortality divided by the lower inoculum density closest to 50% 
mortality is determined (log (3.1 x 105 / 1 x 105)).  This value is then multiplied by the 
proportionate distance value.  The resulting value is added to the value calculated from taking the 
log of the lower inoculum density closest to the 50% mortality value.  This numerical value is 
added in exponential form to a base of 10 to calculate the LD50 value in colony forming units per 
mouse.     
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Table 3. Desired Inoculum Concentration for Long-Term LD50. 
 
 
 
 
1244-47(pUCP19exoUspcU) 
(CFU) 
 
 
 
1.5 x 107
  
 
3.0 x 105 
 
 
 
1.5 x 106 
 
 
 
1.5 x 105 
 
 
 
6.5 x 105 
 
  
 
1.0 x 105 
 
 
 
5.0 x 105
 
 
1.5 x 104 
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Table 4. Desired Inoculum Concentration for Short-Term LD50. 
 
 
 
 
1244 
(pUCP19 
exoUspcU) 
(CFU) 
 
1244 
(CFU)
 
1244G7 
(pUCP19 
exoUspcU) 
(CFU)
 
1244G7 
(CFU)
 
1244-47 
(pUCP19 
exoUspcU) 
(CFU)
 
1244-47 
(CFU)
 
1.0 x 107 
 
 
 
7.0 x 106 
 
 
1.0 x 107  
 
7.5 x 106 
 
 
1.0 x 107 
 
 
1.0 x 107 
 
 
1.0 x 106 
   
 
3.0 x 106 
 
 
1.0 x 106 
 
 
 
4.0 x 106 
 
 
5.0 x 106 
 
 
7.0 x 106 
 
 
5.0 x 105
   
 9.0 x 105 
 
  
1.0 x 106 
 
 
5.0 x 106 
 
 
 
1.0 x 105 
 
 
  
1.0 x 105 
 
  
5.0 x 105 
 
 
 
  
 1.0 x 104 
 
  
1.0 x 104 
 
 
  
 1.0 x 105 
 
 
 
 
 
 
 
 
 
 
 48
 
 
 
Table 5. Protocol for the Long-Term LD50 Study. 
 
 
 
DAY PROCEDURE
1 Female balb/c mice arrive at Duquesne University Animal Facility 
1-3 Mice acclimate to the Animal Facility 
4 Mice are administered 10 µl/nare of sterile PBS 
11 Mice are administered 10 µl/nare of sterile PBS 
18 Mice are administered 10 µl/nare of the desired inoculum 
18-21 Mice are monitored for death 
 
 
 
 
 
 
 
 
Table 6. Protocol for the Short-Term LD50 Study. 
 
 
 
DAY PROCEDURE
1 Female balb/c mice arrive at Duquesne University Animal Facility 
1-3 Mice acclimate to the Animal Facility 
4 Mice are administered 10 µl/nare of desired inoculum 
4-7 Mice are monitored for death 
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 Table 7. Example Survival Data for LD50 Calculation 
 
 
 
 
 
 
 
10012 0405.2 x 106
1008 0409.3 x 105
1004 0403.1 x 105
00 4041 x 105
00 8042.1 x 104 
% Mortality (f)Dead (e) Alive (d)Dead (c)Alive(b)Inoculum Density (a) 
  Total 1244(pUCP19exoUspcU) 
 
 
 
3.  Competition Assay 
In order to measure the effect glycosylation has on the virulence of P. aeruginosa, 
colonization of a murine model of acute pneumonia was assessed in a competition assay.  
Previous work has demonstrated the practicality of utilizing a murine model of acute pneumonia 
and the sensitivity of a colonization test such as a competition assay to compare virulence among 
various bacterial strains (Comolli et al., 1999; Allewelt et al., 2000).  The current assay tests for 
a difference in the efficiency of colonization based on the presence of glycosylated pili.   
P. aeruginosa strains 1244(pUCP19exoUspcU) and 1244G7(pUCP19exoUspcU) were 
grown on TSA Cb250 plates for 10 hours at 37ºC.  Approximately 8 ml of sterile PBS was added 
to each plate.  The plates were maintained in constant motion on a VWR Scientific waiver 
(Asheville, NC) for 5 to 10 minutes.  This allowed to bacteria to be suspended in the PBS.  Using 
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a sterile 25 ml pipette, the suspension was carefully collected and placed in a sterile 15 ml tube.  
The large 25 ml pipette was used to prevent the breakage of pili that may have resulted from 
being “sucked” into the hole of a smaller pipette.  The optical density of each strain was 
normalized by adjusting the absorbance at a wavelength of 650 nm to approximately 0.500.  
After diluting the bacteria in PBS to get the desired concentration of 5 x 105 CFU/mouse, 500 ml 
of each strain was mixed.  This inoculum was administered to six mice intranasally as previously 
described.   
The experiment was terminated by subjecting the mice to CO2 exactly 12 hours after 
administration of the challenge.  Once death occurred, colonization of the organs was assessed 
(Comolli et al., 1999).  An incision was made along the rib cage and abdomen of each mouse.  
Using the aseptic technique, the lungs, liver, and spleen of each mouse were removed.  The 
organs were placed in sterile 1.5 ml eppendorf tubes and kept on ice.  Prior to homogenization, 
each organ was weighed.  1 ml of NB (nutrient broth) was added to each organ and the organ 
was homogenized using an Omni TH International homogenizer (Marietta, GA).  Once the organ 
was homogenized, ten-fold serial dilutions were made in NB.  Using a hockey stick to employ 
the spread plate technique, 100 µl of each dilution was plated in duplicate on both TSA Cb250 and 
TSA Cb250 Gm100 plates and grown at 30ºC for approximately 24 hours.  Bacterial colonies were 
enumerated in order to determine which strain had greater success in colonizing the mouse 
tissue. 
A χ2-test was used to analyze the significance of the differences in total bacteria 
recovered from the lungs for each strain.  The expected value was derived from the ratio of 
1244(pUCP19exoUspcU) to 1244G7(pUCP19exoUspcU) administered in the initial inoculum.  
This value, known as the challenge index, was 2.49.  The observed value was calculated as a 
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ratio of the amount 1244(pUCP19exoUspcU) and 1244G7(pUCP19exoUspcU) recovered from 
the lungs.   
E. Nonopsonic Phagocytosis Assay 
1. Preparation of Polymorphonuclear Leukocytes (PMN) 
Approximately 8 ml of fresh human blood was collected in a heparinized tube.  Equal 
volumes of blood and heparin/dextran buffer (4.5 g/500 ml NaCl, 28.4 mg Heparin, and 10 g 
Dextran 500) were mixed in a sterile tube and incubated at 37ºC for 1 hour.  At this point, the 
blood separates into two distinct phases.  A red pellet containing the red blood cells forms at the 
bottom of the tube.  At the top of the tube, a yellowish liquid layer containing the leukocytes is 
formed.  The top liquid layer was removed and centrifuged (4000 rpm/10 minutes/26ºC/SS-34 
Sorvall rotor) to gather the white blood cells (WBC).  The pellet was suspended in RPMI-1640 
media (Hyclone; Logan, Utah) to the original plasma volume.  The sample was centrifuged once 
again and resuspended in the same volume of lysing buffer (1 % NaCl).  After incubating at 
room temperature for 10 minutes, the sample was centrifuged two more times under the same 
conditions and resuspended in the same volume of RPMI-1640 media.  In order to determine the 
density of the PMN’s, white blood cells were counted using a hemocytometer (4 x 10-3 µl/block).  
The white blood cells were then centrifuged and diluted in RPMI-10% heat-inactivated Fetal 
Bovine Serum (FBS) (Hyclone; Logan, Utah) to the desired concentration of 2 x 105 WBC/ml.   
2. Preparation of Bacteria 
Overnight cultures of PA1244, PA1244G7, E. coli HB101, and PAwbpL were prepared 
on NA plates.  In order to harvest the cells, 8 ml of sterile RPMI-1640 media was added to each 
plate and the plate was set on a waiver for 10 minutes.  The cell suspension was gently collected 
with a 25 ml serological pipette and the density of each strain was normalized to 0.500 at a 
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wavelength of 650 nm.  These conditions resulted in approximately 1 x 109 cells/ml.  Bacterial 
cells were diluted in RPMI-10% heat-inactivated FBS to result in a ratio of 50-100 bacteria per 
white blood cell. 
3. Phagocytosis Assay 
Twelve-millimeter ethanol-washed round coverslips were placed in the wells of a sterile 
24-well tissue culture plate.  One milliliter of leukocytes (2 x 105 WBC/ml) was added to each 
coverslip and incubated for 2 hours at 37ºC in 5 % CO2.  Adherent macrophages were washed by 
injecting and aspirating 1 ml of PBS on the coverslip.  The coverslip was incubated in 450 µl of 
phosphate-buffered phagocytic medium (138 mM NaCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4,  
2.7 mM KCl, 1 mM MgCl2, 0.6 mM CaCl2 and 10 mM D-glucose) at 37ºC for 30 minutes.  Fifty 
microliters of bacteria were added to each coverslip and ingestion was allowed to proceed for 1 
hour at 37ºC.  Following incubation, the coverslip was washed six times in PBS as previously 
described.   Each coverslip was either fixed immediately in methanol or subjected to a lysozyme 
treatment.  The lysozyme treatment required that the coverslips be transferred to a pre-chilled 24-
well culture plate and incubated with 500 µl of ice-cold lysozyme (5 mg/ml) for 5 minutes on 
ice.   After washing the coverslip in 1 ml of PBS, each coverslip was incubated for 2 minutes in 
500 µl of ice-cold deionized water.  The coverslips were washed with PBS and the cells were 
fixed with methanol.   
Coverslips were stained with crystal violet and analyzed under the phase contrast 
microscope.  The number of bacteria phagocytosed per white blood cell was enumerated for each 
strain.  A one-way ANOVA in addition to a Bonferroni’s Multiple Comparison Test were 
utilized to analyze the variance in nonopsonic phagocytosis between the different bacterial 
strains (Speert et al., 1984).   
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III. Results 
Studies have suggested that carbohydrate modifications on proteins can play a role in 
adhesion, protection against proteolytic cleavage, solubility, antigenic variation, and protective 
immunity (Szymanski et al., 2002).   This phenomenon has been demonstrated in the Gram-
negative bacteria N. meningitidis and Campylobacter in which glycosylated pili have been 
shown to protect the bacterium from various components of the host immune system (Virji 1993 
et al.; Szymanski et al., 1999).  Presumably, the glycosylated pili of P. aeruginosa play a similar 
role in protection against the host defenses.  In attempts to establish the pilin glycan’s role in P. 
aeruginosa pathogenesis, experiments were conducted utilizing a murine model of acute 
pneumonia and components of the mammalian immune system.  
A. Can Pseudomonas aeruginosa 1244 be Manipulated to Increase Virulence? 
Experimental Design 
Initial experiments have shown the LD50 values of P. aeruginosa strains 1244, 1244G7, and 
1244-47 to be relatively high, ranging from 5.20 x 106 CFU/ml to 6.29 x 106 CFU/ml (Horzempa, 
unpublished).  These high LD50 values pose complications when performing survival and 
immunological assays utilizing these strains.  Specifically, having a high concentration of 
bacteria in your challenge may cause non-specific death, such as that related to inflammation.  
Research conducted in 2000 has demonstrated that the acquisition of the exoU gene by P. 
aeruginosa increases bacterial virulence as seen by a dramatic 100-fold reduction in 50% lethal 
dose (LD50) values (Allewelt et al., 2000).  By transforming this type III effector protein into P. 
aeruginosa 1244, one would be able to use a lower challenge concentration and still see 
cytotoxic effects in the host.  Based on this finding, the aim of this first section of research was 
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to assess LD50 values to determine if acquisition of the exoU gene increases the virulence of P. 
aeruginosa strains 1244, 1244G7 and 1244-47.   
1. Does P. aeruginosa 1244 already possess the exoU gene? 
In order to verify the absence of the exoU gene from the wild-type P. aeruginosa 
1244, chromosomal DNA was extracted and tested from strains PA1244, PA103, and PA01.  
PA103, a strain possessing the exoU gene (McMorran et al., 2003), served as the positive control 
while a strain lacking the exoU gene, strain PA01, was selected as the negative control 
(Holloway, 1955).  From here, the chromosomal DNA was exposed to 36 amplification cycles 
and run on a 0.8% agarose gel to assess the PCR (Figure 9).  In the lane containing the PCR 
product from the PA103 positive control (lane 2), a band can be detected that is comprised of 
about 428bp corresponding to the expected location of the exoU gene.  In the lane containing the 
PCR product for the PA01 negative control (lane 3), the absence of a band demonstrated the 
absence of the exoU gene in PA01.  As for the experimental sample in lane 4, the absence of the 
exoU gene from PA1244 was confirmed by the absence of a PCR product on the agarose gel.  
Because the controls worked properly, it is suggested that the P. aeruginosa 1244 strain lacks 
this type III effector protein.    
2. Can PA1244 acquire the exoU gene? 
 The transformation of pUCP19 and pUCP19exoUspcU into PA1244, PA1244G7 and 
PA1244-47 was done via electroporation.  In order to determine the efficiency of the 
electroporation, a transformation efficiency had to be calculated.  The raw colony counts can be 
found in the Appendix in Table A1.  Table 8 contains a listing of the average number of 
transformants in each strain.  Overall, the transformation was a success with the pUCP19 
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plasmid having 16847 transformants/µg plasmid DNA and the pUCP19exoUspcU plasmid 
having 2497 transformants/µg plasmid DNA.   
 
 
 
 
 
 
  
 
428 bp Æ  
 
 
1         2         3          4 
 
 
 
 
Figure 9.  DNA Agarose Gel of PCR on Chromosomal DNA Confirming the Absence of 
exoU from PA1244.  Chromosomal DNA was extracted and subjected to PCR to demonstrate 
the absence of the exoU gene from PA1244.  Lane 1 contains the molecular weight standard λ 
HindIII.  Lane 2 contains the PCR product for the positive control PA103 possessing the 428 
base pair exoU gene.  Lane 3 contains the PCR product for the negative control PA01 that lacks 
the exoU gene.  Lane 4 contains the PCR product for the wild-type PA1244.  These results show 
that strain PA1244 lacks the exoU gene.  The arrow indicates the expected location of the band 
representing the exoU gene.  The agarose gel was stained with ethidium bromide for viewing. 
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Average Number of Transformants 
 
 
Bacterial Strain 
 
 
Average Number of Transformants/µg of 
Plasmid DNA 
 
 
1244G7(pUCP19) 
 
 
860 transformants/µg DNA 
 
1244G7(pUCP19exoUspcU) 
 
 
53 transformants/µg DNA 
 
1244-47(pUCP19) 
 
 
12400 transformants/µg DNA 
 
1244-47(pUCP19exoUspcU) 
 
 
1069 transformants/µg DNA 
 
1244(pUCP19) 
 
 
37280 transformants/µg DNA 
 
1244(pUCP19exoUspcU) 
 
 
6368 transformants/µg DNA 
 
 
 
Table 8. Transformation Efficiency for Electroporation Involving the exoU Gene.  The 
number of transformants was determined by plating the electroporated cells onto LB Cb250 plates 
and enumerating the colony forming units.  The transformation efficiency was calculated by 
determining the number of transformants per microgram of DNA in the sample. 
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3. Does the exoU gene increase the virulence of PA1244? 
Although LD50 values for P. aeruginosa 1244, 1244G7, and 1244-47 exoU- strains 
were previously determined (Horzempa, unpublished), LD50 studies on these strains were 
extended to provide a more reliable estimation of the LD50 values.  An enumeration of the 
colonies resulting from the diluted inoculum plated on TSA Cb250 was performed to determine 
the exact amount of bacteria administered to the mice on the day of the inoculation.  Table 9 
provides a listing of the exact inoculum concentrations administered to the mice.  The colony 
counts used to determine the actual concentration of the inoculum administered to the mice are 
found in Table A2 in the Appendix. 
Once LD50 values were determined, these values were incorporated with the previous 
LD50 data (Horzempa, unpublished) to determine a more reliable LD50 value for each strain.  At 
this point, the bacterial strains containing the exoU gene were utilized to determine LD50 values 
as in Allewelt et al. (2000).  Table 10 provides a listing of the exact inoculum densities 
administered to the mice for the LD50 study involving the exoU gene.  The colony counts used to 
determine the actual density of the inoculum administered to the mice in the LD50 study 
involving the exoU gene are found in Table A3 in the Appendix.  Table 11 provides the 
inoculum densities and their associated survival data that were utilized in determining an LD50 
value as per the equation employed by Reed and Muench (1938).  The estimated LD50 values for 
P. aeruginosa 1244, 1244G7, and 1244-47 with and without the exoU gene are found in 
Table 12.  The LD50 values for all three P. aeruginosa strains without the exoU gene ranged from  
5.20 x 106 CFU/20 µl to 6.29 x 106 CFU/20 µl whereas the LD50 values with the exoU gene 
ranged from 1.76 x 105 CFU/20 µl to 2.90 x 105 CFU/20 µl.  Overall, it appears that acquisition 
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of the exoU gene makes these P. aeruginosa strains more virulent as seen by a 10-fold decrease 
in LD50 values.   
 
 
 
 
 
 
 
 
 
Actual Inoculum Concentration for Short-Term LD50
 
 
1244 
(CFU) 
 
 
1244G7 
(CFU)
 
1244-47 
(CFU)
 
3.6 x 106
 
2.8 x 106
 
4.3 x 106
 
 
2 x 106
 
 
1.4 x 106
 
3.7 x 106
   
3.5 x 106
 
 
 
 
 
Table 9. Actual Inoculum Concentrations for Short-Term LD50 of PA1244, PA1244G7, and 
PA1244-47.  The actual concentration of the inoculum administered to the mice in the LD50 
study was determined after assessing colony counts on TSA plates.  The concentrations listed 
above are the total amount of colony forming units per 20 µl. 
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Actual Inoculum Concentrations for Short-Term LD50 Utilizing exoU
 
1244(pUCP19exoUspcU) 
(CFU) 
 
 
1244G7(pUCP19exoUspcU) 
  (CFU)
 
1244-47(pUCP19exoUspcU)
(CFU)
 
5.2 x 106
 
3.8 x 107
 
1.06 x 107
 
 
9.3 x 105
 
 
4.1 x 106
 
8.4 x 106
 
3.1 x 105 
 
 
1 x 105    
 
 
2.1 x 104 
 
 
2.7 x 105 
 
 
2.7 x 105 
 
 
4.6 x 104
 
4.1 x 105 
 
 
2.05 x 105 
 
 
9.6 x 104
 
 
 
 
 
 
Table 10. Actual Inoculum Concentrations for Short-Term LD50 of PA1244(pUCP19exoU 
spcU), PA1244G7(pUCP19exoUspcU), and PA1244-47(pUCP19exoUspcU).  The actual 
concentration of the inoculum administered to the mice in the LD50 study was determined after 
assessing colony counts on TSA Cb250 plates.  The concentrations listed above are the total 
amount of colony forming units per 20 µl. 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
10012 040 5.2 x 106
1008 040 9.3 x 105
1004 040 3.1 x 105
00 404 1 x 105
00 804 2.1 x 104 
% MortalityDead AliveDeadAliveInoculum Density 
  Total 1244(pUCP19exoUspcU)  
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
10012 040 3.8 x 107
1008 040 4.1 x 106
1004 040 2.7 x 105
00 404 2.7 x 105
00 804 4.6 x 104 
% MortalityDead AliveDeadAliveInoculum Density 
  Total 1244G7(pUCP19exoUspcU)  
 
(c) 
 
 
 
 
 
 
 
 
 
 
 
 
Table 11. Survival Data for LD50 Studies Utilizing Strains Possessing ExoU.  These values 
were used in the Reed and Muench equation to determine an LD50 value (Reed et al., 1938).  See 
Materials and Methods for a detailed description. 
10012 040 1.06 x 107
1008 040 8.4 x 106
1004 040 4.1 x 105
00 404 2.05 x 105
00 804 9.6 x 104 
% MortalityDead AliveDeadAliveInoculum Density 
  Total 1244-47(pUCP19exoUspcU)  
  
 61
 
LD50 Values
Bacterial Strain LD50
 
PA1244 
PA1244(pUCP19exoUspcU) 
 
* 6.29 x 106 
   1.76 x 105
PA1244G7 
PA1244G7(pUCP19exoUspcU) 
 
* 6.1 x 106 
   2.7 x 105 
 
 
PA1244-47 
PA1244-47(pUCP19exoUspcU) 
 
* 5.20 x 106 
   2.90 x 105
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 12. LD50 Values of P. aeruginosa. The LD50 values for P. aeruginosa strains 1244, 
1244G7 and 1244-47 both with and without the exoU gene have been determined after 
performing a three-day study on the virulence of each strain.  LD50 values corresponding to the 
strains lacking the exoU gene are relatively large.  After acquisition of the type III effector 
protein ExoU, the P. aeruginosa strains become more virulent as indicated by a decrease in the 
LD50 value for all three strains.  * Denotes values determined by incorporating unpublished work 
by Horzempa conducted at a different time. 
 
 
 
 
 
 Furthermore, experiments were conducted to ensure that the exoU gene could maintain its 
virulence in the P. aeruginosa strains after an extended period of time.  In order to verify that the 
LD50 values remain static through time, a long-term LD50 study was performed on strain 
PA1244-47(pUCP19exoUspcU).  As compared to the previous short-term LD50 studies, the long-
term involved a two-week period in which the mice were administered a sham inoculum 
consisting of PBS.  The bacteria were not administered until the third week.  Table 13 provides 
the actual inoculum densities administered to the mice for the long-term LD50 study.  Table A4 in 
the Appendix provides the colony counts used to calculate the actual densities.  Table 14 
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provides a breakdown of the mice survival status for each inoculum that was used to calculate 
the LD50 value based on the Reed and Munch equation.  The LD50 value for 1244-47(pUCP19 
exoUspcU) in the long-term study can be found in Table 15.  Fortunately, it appears as though 
time does not affect the virulence of the ExoU protein.  This type III effector protein enhances 
the virulence of P. aeruginosa just the same in one week as it does in three weeks. 
 
 
 
 
 
 
 
 
Actual Inoculum Concentrations for Long-Term LD50 Utilizing exoU 
 
 
1244-47(pUCP19exoUspcU) 
(CFU) 
 
 
7.4 x 105
  
5.8 x 105 
 
 
4.1 x 105 
 
 
2.4 x 105 
 
 
6.4 x 104 
 
 
4. 7 x 103
  
2.25 x 104 
 
 
4.55 x 102
 
Table 13. Actual Inoculum Concentrations for Long-Term LD50 of PA1244-47(pUCP19 
exoUspcU).  The actual concentration of the inoculum administered to the mice in the LD50 study 
was determined after assessing colony counts on TSA plates.  The concentrations listed above 
are the total amount of colony forming units per 20 µl. 
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00 1404 4.7 x 103
1007 030 5.8 x 105
1009 020 7.4 x 105
1004 040 4.1 x 105
00 303 2.4 x 105
00 704 6.4 x 104
00 1003 2.25 x 104
00 1804 4.55 x 102
% MortalityDead AliveDeadAlive Inoculum density 
  Total1244.47(pUCP19exoUspcU)
 
Table 14. Live/Dead Analysis for Long-Term LD50 Study utilizing 1244-47(pUCP19exoU 
spcU).  A percent mortality was determined after calculating the number of mice that survived 
each inoculum dosage.  These values were used in the Reed and Munch equation to determine an 
LD50 value. 
 
 
 
 
 
 
 
 
PA1244-47(pUCP19exoUspcU) LD50 
 
Short-Term LD50                     Long-Term LD50 
 
2.90 x 105 CFU          1.62 x 105 CFU 
 
 
 
Table 15. PA1244-47(pUCP19exoUspcU) LD50 Values.  The virulence associated with the 
exoU gene is independent of the length of the experiment.  The short-term LD50 study was 
conducted over the course of one week, with three days being the actual experimental period.  
The long-term LD50 study was conducted over the course of three weeks.  The first two weeks of 
the long-term study involved administration of a sham inoculum.  The bacteria were not 
administered to the mice until the third week of the experiment. 
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B. Does the Pilin Glycan Play a Role in the Pathogenesis of P. aeruginosa? 
 
Experimental Design 
As demonstrated in the LD50 studies, the murine model of acute pneumonia is a well-
established system to assess the virulence of P. aeruginosa.  This respiratory model provides an 
ideal environment for studying P. aeruginosa pathogenesis because it mimics aspects of the 
clinical development of pneumonia as seen in cystic fibrosis patients.  Specifically, it provides an 
environment in which pili are of most importance to aid the bacterium in adhesion to the 
epithelial surfaces of the respiratory tract.  By binding, the pili are able to mediate colonization 
and initiate infection (Merz et al., 2000).   
Moreover, it has been proposed that the glycosylation of pili, as well as other appendages, 
associated with Gram-negative bacteria play a role in protecting the microorganism from the host 
immune system (Virji et al., 1993; Szymanski et al., 1999; Arora et al., 2005).  Furthermore, the 
results of the LD50 studies suggested that glycosylated pili contribute to the virulence of P. 
aeruginosa by allowing for an even lower LD50 value for strain PA1244(pUCP19exoUspcU) 
possessing glycosylated pili when compared to strain PA1244G7(pUCP19exoUspcU) possessing 
non-glycosylated pili.  This evidence of glycosylation affecting the virulence of P. aeruginosa 
has established the aim of the next set of experiments.  Similar to research conducted by Allewelt 
in 2000, a competition assay utilizing a murine model of acute pneumonia was employed as a 
sensitive means of assessing colonization to determine if the pilin glycan increases the virulence 
of P. aeruginosa.   
 
 
 
 65
1. Will the Pilin Glycan of PA1244(pUCP19exoUspcU) Aid in Colonization? 
       As in the LD50 studies, the actual inoculum for each bacterial strain had to be 
calculated (Table 16).  Table A5 in the Appendix provides the colony counts that were used to 
determine the actual inoculum densities.  Although relatively close to the desired value of 5 x 105 
CFU/ml, the inoculum density of 1244(pUCP19exoUspcU) and 1244G7(pUCP19exoUspcU) 
varied.  To account for this variation, a challenge index was established.  It was determined that 
there were 2.49 times more 1244(pUCP19exoUspcU) bacteria administered to the mice than 
1244G7(pUCP19exoUspcU) bacteria.    
In order to assess colonization, the mice were sacrificed 12 hours after the challenge 
and the numbers of PA1244(pUCP19exoUspcU) and PA1244G7(pUCP19exoUspcU) present in 
the lung, liver, and spleen were determined on the basis of gentamicin resistance of PA1244G7.  
Unfortunately, analysis of the spleen and liver at this time produced low and non-significant 
values for either strain, indicating that dissemination had not occurred at this dosage and time 
point.  For this reason, only the lung tissue was further analyzed.  Table A6 in the Appendix 
provides the lung weights used to determine the amount of each bacterial strain recovered per 
gram of lung tissue (Table 16).  Table A7 in the Appendix provides the raw colony counts used 
to determine the amount of bacteria present in each organ.  In addition, a competitive index 
(Comolli et al., 1999) has been determined by calculating the ratio of 1244(pUCP19exoUspcU) 
to 1244G7(pUCP19exoUspcU) recovered from the lung and comparing it to the ratio of 
1244(pUCP19exoUspcU) to 1244G7(pUCP19exoUspcU) in the inoculum (2.49).  A competitive 
index greater than 2.49 would indicate that 1244(pUCP19exoUspcU) could better colonize the 
lung, while a ratio of less than 2.49 would suggest that 1244G7(pUCP19exoUspcU) was more 
efficient in colonization.  Chi-square analysis utilizing the corrected values indicated that 
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significantly more of strain 1244(pUCP19exoUspcU) survived in the mouse lung 12 hours 
following inoculation than did strain 1244G7(pUCP19exoUspcU) (χ2=87.91, d.f. =5, P<0.001).  
The results of this mathematical analysis indicated that the observed differences in colonization 
between the two P. aeruginosa strains are significant.  Furthermore, this data showed that, on 
average, strain 1244(pUCP19exoUspcU) was more successful in the environment provided by 
the respiratory model by a factor of 3.44 (average of competitive ratios in Table 16).  Altogether, 
these results indicated that the presence of the pilin glycan promotes lung colonization by strain 
1244(pUCP19exoUspcU). 
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Relative Colonization: CFU/gram of Lung Tissue 
 
 
Animal 
 
 
1244exoU+
 
  
1244G7exoU+
 
Ratio
 
Competitive Index 
 
 
1 1.43 x 106 1.48 x 105 9.7 
 
4.29 
2 2.95 x 105 8.75 x 104 3.4 1.76 
3 1.46 x 106 1.37 x 105 10.7 4.56 
4 3.72 x 105 7.25 x 104 5.1 2.05 
5 9.19 x 104 1.38 x 104 6.7 3.09 
6 6.76 x 105 6.08 x 104 11.1 4.87 
 
 
 
Table 16.  Relative Colonization by PA1244(pUCP19exoUspcU) and PA1244G7 
(pUCP19exoUspcU) using the Murine Respiratory Model.  The amount of 
1244(pUCP19exoUspcU) exceeds 1244G7(pUCP19exoUspcU) in all six of the mice. A ratio 
greater than 2.49 indicates that PA1244(pUCP19exoUspcU) is better at colonizing than 
PA1244G7(pUCP19exoUspcU).  The competitive index adjusts for differences in initial 
inoculum density based on the challenge index of 2.49. 
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C. What is the Mechanism by which PA1244 Increases Virulence? 
  Experimental Design 
Normally, phagocytosis involves the action of opsonins such as antibodies and 
complement to enhance the ingestion of bacteria.  However, studies have shown that 
phagocytosis can occur by relying solely on the white blood cells ability to recognize distinct 
features associated with pathogens (Speert et al.,1984).  In one such study, it was demonstrated 
that in the absence of these opsonins, phagocytosis resulted from the recognition of pili 
associated with certain bacterial strains (Speert et al., 1986).  In fact, this study showed that 
bacterial strains possessing pili are more easily phagocytosed due to enhanced attachment of the 
bacterium to the leukocyte mediated by the pili.  In an attempt to determine if the glycan 
associated with pili of PA1244 plays a role in phagocytosis, a nonopsonic phagocytosis assay 
was performed.   
1.  Does the Pilin Glycan Inhibit Nonopsonic Phagocytosis? 
When assessed by visual inspection mediated by phase contrast microscopy, it appears as 
though both the E. coli HB101 and the P. aeruginosa wbpL positive controls were actively 
phagocytosed.  These strains should be susceptible to phagocytosis due to the absence of an O-
antigen (Boyer et al., 1969).  Further controls included coverslips containing only bacteria and 
coverslips containing only white blood cells.  These controls ensured that the cells were being 
correctly identified during assessment.  To prevent any bias, ten white blood cells were randomly 
assessed from each strain.  In both control specimens, the process of phagocytosis was observed 
as either in the initial stages of attachment to the white blood cell or in the latter stages of 
ingestion by the white blood cell.  Table A8 in the Appendix provides the phagocytosis counts 
assessed as bacteria per white blood cell.  Figure 10 provides micrographs of PA1244, 
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PA1244G7 and one of the controls E. coli HB101 demonstrating phagocytosis.  To verify 
accuracy when determining the number of ingested bacteria per white blood cell, counts were 
only taken from those samples exposed to the lysozyme treatment.  This method ensured that the 
bacteria being counted were actually phagocytosed and not just bacteria that adhered to the white 
blood cell.  After assessing the number of bacteria engulfed by the white blood cells, it was 
evident that the pilin glycan of PA1244 inhibited phagocytosis as indicated by a lack of the 
number of ingested bacteria.  When compared to PA1244G7, almost none of the PA1244 
bacteria were ingested by white blood cells.  In order to determine if these results were 
significant, an ANOVA analysis along with a Bonferroni’s Multiple Comparison Test was 
performed (Figure 11).  Statistical analysis demonstrated that the variance in phagocytosis seen 
in PA1244 compared to PA1244G7 and the control strains is significant (F=64.23; d.f. =3; 
p<0.0001).  Furthermore, when comparing just PA1244 and PA1244G7, the results remained 
significant (p<0.05) strongly suggesting that the glycan is important in avoiding phagocytosis.  
In fact, the results of the Bonferroni’s Multiple Comparison Test showed that each of the four 
strains significantly varied from each other in the amount of bacteria that were phagocytosed.  
Overall, these results indicate the possibility that this is the mechanism by which the glycan 
increases virulence.  
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Figure 10. Micrograph Illustrating Nonopsonic Phagocytosis (100X).  (A, D, G) Bacteria 
stained with crystal violet.  (B, E, H) Bacteria being phagocytosed by a white blood cell. (C, F, 
I) Phagocytosis of bacteria by a white blood cell as seen in a lysozyme treatment. (J) White 
blood cells (40X). 
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Figure 11. Assessment of Phagocytosis Comparing Strains PA1244 and PA1244G7.  Each 
bar represents an average number of bacteria phagocytosed by white blood cells based on counts 
from ten white blood cells.  E. coli HB101 and PAwbpL served as the positive controls.  PA1244 
has a significantly lower amount of bacteria phagocytosed by white blood cells compared 
PA1244G7 (P<0.05).  The letter above each bar indicates that each strain significantly varied in 
the amount of bacteria that were phagocytosed by the white blood cells.  The brackets located on 
each bar indicate the standard error. 
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IV. Discussion 
Aforementioned, the pili of P. aeruginosa are comprised of small pilin subunits that are 
characteristic of the type IV pili (Craig et al., 2004).  As with any protein, the pilin of P. 
aeruginosa is capable of partaking in a post-translational modification and does so by covalently 
binding to an acidic carbohydrate moiety (Comer et al., 2002).  This entity, known as the pilin 
glycan, is a trisaccharide encoded by the pilO gene (Castric, 1995).  Since its discovery in 1995 
(Castric, 1995), much research has been conducted in attempts to identify the role of the pilin 
glycan in P. aeruginosa pathogenesis.  This research provides another attempt in determining the 
role of the glycan in P. aeruginosa pathogenesis.   
A. Assessment of LD50 Values Following Acquisition of the exoU Gene 
A possible method of analyzing the role of the pilin glycan in P. aeruginosa pathogenesis is 
to conduct immunological assays to assess how this modification affects the bacterium in the 
presence of host defenses.  The employment of this type of assay has disadvantages in that it can 
elicit non-specific responses such as inflammation that may become excessive and result in 
death.  This type of situation can lead to the flawed conclusion that the bacterial infection caused 
the death when in fact the death resulted from some other factor.  To avoid the possibility of 
skewed results, one must determine a way to be certain that death can be attributed to the 
bacterial strain under speculation.  One approach to obtaining this goal is to increase the 
virulence of the bacterial strain of interest.  If the strain is more virulent, the concentration of 
bacteria used in the assay can be lowered.  Moreover, the onset of the cytotoxic effects 
associated with the bacteria will be more rapid making it more likely that death will occur from 
the actual infection rather than a non-specific response to the infection.   
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A proven method of increasing the virulence of a strain is through the acquisition of 
cytotoxic genes.  In vitro and in vivo studies of ExoU, a protein encoded by the exoU gene and 
secreted by the type III secretion system of P. aeruginosa, have demonstrated a correlation of 
this type III effector protein with cytotoxic activity leading to lung injury, bacterial 
dissemination, and sepsis in both animal and human infection (Phillips et al., 2003).  Other 
studies have demonstrated an increase in virulence observed as a decrease in LD50 values 
associated with bacterial strains that acquired the exoU gene (Allewelt et al., 2000).  Based on 
these findings, the intent of the current research was to transform the exoU gene into PA1244 
with the hope of increasing the virulence as indicated by a reduction in the LD50 value.  
Comparing LD50 values of strains lacking the exoU gene with strains possessing the exoU 
gene provides a practical method to assess virulence.  As indicated in this work, it is clear that 
the type III secretion protein ExoU does increase virulence of PA1244.  Therefore, as shown in 
Table 12, it takes fewer bacteria to have a lethal effect on half of the experimental population 
when the exoU gene is present.   
Virulence associated with ExoU can be attributed in part to its mode of delivery.  Being a 
protein that is secreted by the type III secretion system, ExoU is delivered directly into the host 
cell via a needle-like complex.  This type of delivery makes it near impossible for the host 
immune system to destroy the toxin before it enters an epithelial cell.  Once inside the host cell, 
the exotoxin can modulate actin cytoskeleton dynamics to prevent phagocytosis and decrease 
macrophage viability (Coburn et al., 1999; Galan et al., 1999).  In the absence of phagocytosis, 
the bacteria can adhere to epithelial cells and establish an infection inside the host.  Also, ExoU 
can modulate inflammation and interfere with cell signaling (Cornelis et al., 2000).  If there is 
interference in the cell signaling within the host, the host immune system may not properly 
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destroy the bacteria.  Furthermore, septic shock has been associated with the translocation of 
ExoU into the host (Coburn et al., 1999).  With the inhibition of host immune functions, it is no 
wonder the secretion of the ExoU protein makes the strain more virulent.  A strain secreting the 
ExoU protein is able to manipulate the host to its advantage by destroying immune mechanisms.  
Because the challenge of the immune system is lessened, these strains are able to effectively 
colonize the host and exhibit virulence.  
 In addition, unpublished data by Horzempa has shown that the LD50 values of P. aeruginosa 
strains lacking the exoU gene have varied depending on the length of the experiment.  This 
phenomenon could be a complication when conducting lengthy experiments that are dependent 
on the P. aeruginosa strain having a certain virulence.  In order to ensure that LD50 values of P. 
aeruginosa strains possessing the exoU gene remain static, long-term LD50 studies taking place 
over the course of three weeks were compared to short-term LD50 studies taking place over the 
course of three days.  When comparing the long-term LD50 study with the short-term LD50 study, 
it appears as though the length of an experiment does not affect virulence.  Experiments 
conducted over the course of three days and experiments conducted over the course of three 
weeks both demonstrated an increase in virulence associated with the exoU gene.  
These results show promise for the use of the exoU gene in studies requiring a more virulent 
strain of P. aeruginosa.  One specific application of this finding is in the development of a P. 
aeruginosa vaccine.  Utilization of a more virulent strain of P. aeruginosa would allow for the 
administration of a low booster dose for the entire course of the immunization.  This is a crucial 
finding since repeated immunization is required over the course of a few weeks to allow for 
clonal proliferation of antigen-specific T cells or B cells (Goldsby et al., 2001).    
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Furthermore, the results of the LD50 study demonstrate that pili may play a role in the 
pathogenesis of P. aeruginosa.  The LD50 value for strains PA1244 and PA1244G7 possessing 
pili is lower than the LD50 value for strain PA1244-47 lacking pili.  Moreover, the LD50 value for 
strain PA1244 possessing glycosylated pili is lower than the LD50 value for strain PA1244G7 
possessing non-glycosylated pili.  This phenomenon will be analyzed and discussed in great 
detail in the next experiment involving a competition assay.   
Future direction in this area could include the use of other type III secretion proteins to assess 
the virulence of various P. aeruginosa strains.  In fact, one might try transforming all of the 
known type III effector proteins into PA1244 to see if the LD50 value decreases.  These 
experiments can be conducted in a similar manner utilizing a murine model of acute pneumonia.  
In addition, a western blot analysis of P. aeruginosa strains isolated from mice utilized in the 
LD50 studies could be performed to quantify the amount of ExoU secreted from each strain.  This 
would be a valuable assessment due to the detrimental effects of secreted ExoU on the host.    
B. A Competition Assay Demonstrates an Advantage for the Pilin Glycan 
Interestingly, adjacent to the glycan in the C-terminus of the P. aeruginosa type IV pili is the 
presence of a disulfide loop.  The disulfide loop is a critical structure in pilus adhesion (Lee et 
al., 1994) and is an important B-cell epitope (Comer et al., 2002).  Because of their close 
proximity, it may be possible that the pilin glycan takes on similar roles.  In fact, its distribution 
along the entire length of the pilus (Jewell, 2004) suggests it may be a major contributor to the 
pathogenesis of P. aeruginosa.  In order to determine if the pilin glycan influences the virulence 
of PA1244, a competition assay was performed as a sensitive measure of colonization within a 
murine model of acute pneumonia.   
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Based upon successful colonization, the results presented in this work indicate that the pilin 
glycan of P. aeruginosa 1244 aids in its survival against the host immune system.  When 
comparing the amount of PA1244 (a glycosylated strain) and PA1244G7 (a non-glycosylated 
strain) recovered from the lung of the infected mouse, the amount of PA1244 recovered 
exceeded the amount of PA1244G7 that was recovered.  The competition assay provided 
evidence to strengthen the results from the LD50 study indicating a possible role of glycosylated 
pili in pathogenesis.  This assay demonstrated that PA1244 was more virulent than PA1244G7 
with the advantage of PA1244 being the pilin glycan. 
A possible explanation for the increased virulence associated with the pilin glycan is based 
upon its proximity to the disulfide loop (Lee et al., 1994).  It is speculated that the glycan may 
enhance disulfide loop-mediated pilus adhesion.  It may work to strengthen the binding of the 
bacterium to host epithelial cells (Comer et al., 2002).  In PA1244G7, where the pilO gene is 
absent, the binding between the pili and the host cell may not be as strong as an attachment 
mediated by the pilin glycan.  If this is the case, PA1244G7 may have a harder time remaining 
attached to the host cell when challenged by the immune system.  PA1244, on the other hand, 
has a strong attachment and can effectively colonize the host cell. 
An alternative explanation for the increased virulence associated with the pilin glycan may 
be due to its prime location along the pilus.  Because it is so abundant along the pilus surface, the 
glycan may mask the pilus-binding sites by sterically blocking antibodies from binding.  If 
antibodies are not able to bind to the pilus, the host immune system will not be able to eradicate 
the bacteria from the host.  Thus, that particular strain of bacteria will be able to effectively 
colonize and disseminate in the host.  PA1244G7, on the other hand, does not possess 
glycosylated pili.  In the competition study, this bacterium was not as effective as PA1244 in 
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colonizing the lungs of the murine model of acute pneumonia.  Because the glycan was not 
present along the pilus fiber, the antibody-binding sites were exposed to attacks by the host 
immune system.   
In addition, the formation of a very stable biofilm might also explain why more PA1244 was 
recovered from the lungs of the acute pneumonia model compared to PA1244G7.  The formation 
of a biofilm requires the adhesion of the bacterium to host epithelial cells.  If the adherence is 
stronger than normal in the presence of the pilin glycan, the stability of the biofilm may be 
similarly affected.  Having a stable, intricate matrix of microbial cells provides a “safe-haven” 
against attacks by the host defenses; thereby, strains with this ability are more efficient in 
establishing infection. 
Future direction in this area could include more competition assays to pinpoint the exact 
amount of each bacterial strain present at designated time points.  The procedure presented in 
this work could be followed with the addition of sacrificing the mice every six hours.  This 
would allow for a thorough investigation of the infection process.  Also, the length of the 
competition assay could be extended to 24 hours; however, this would involve the development 
of an optimal inoculum concentration that would allow the mice to survive for an entire day.  In 
addition, the 24-hour competition assay could assess the colonization of systemic organs.  
Aforementioned, the lungs, liver, and spleen were analyzed in this work; however, because the 
experiment was terminated at 12 hours, the liver and spleen did not have sufficient colonization 
to accurately compare virulence between the strains.  Presumably, one would be able to detect 
sufficient growth in these distal organs 24 hours post-infection.  Furthermore, the competition 
assay could be followed up with a clearance assay.  Experiments could be conducted to 
determine how long it would take for the murine model of acute pneumonia to clear an infection.  
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In order to do this experiment, one must determine an optimal inoculum density that would not 
make the mice terminally ill.  Over the course of 24 or 48 hours, at six-hour intervals, the lungs 
would be removed and homogenized to assess how much bacteria can be recovered at a 
designated time point.  One would hope to see a faster decrease in PA1244G7 compared to 
PA1244 due to the presence of the pilin glycan inhibiting immune activity.    
C. Inhibition of Nonopsonic Phagocytosis Associated with the Pilin Glycan 
Studies have suggested that the pili of P. aeruginosa may function as the targets recognized 
by phagocytic cells (Strom et al., 1993).  In fact, it was demonstrated that the pili of P. 
aeruginosa were required for nonopsonic phagocytosis by human neutrophils and monocyte-
derived macrophages (Speert et al., 1986).  Interestingly, it has been shown that phagocytosis of 
P. aeruginosa isolates can be inhibited by the presence of certain sugars (Speert et al., 1984).  In 
order to see if the pilin glycan contributes to the virulence of PA1244 by inhibiting phagocytosis, 
an in vitro nonopsonic phagocytosis assay was conducted. 
In this assay, two different experimental strains of P. aeruginosa were compared to controls 
lacking an O-antigen.  E. coli HB101 and P. aeruginosa wbpL, both lacking the O-antigen, 
served as the positive controls (DiGiandomenico et al., 2002).  In theory, due to the lack of the 
O-antigen providing antigenic variation, the two bacterial strains should be easily phagocytosed 
by white blood cells.  The experimental strains PA1244 containing glycosylated pili and 
PA1244G7 containing non-glycosylated pili were tested to determine if the glycan affected 
phagocytosis.  As described in the results section, fewer PA1244 bacteria were ingested 
compared to the control strains and the P. aeruginosa strain containing non-glycosylated pili.  
These results suggest some sort of protective function of the pilin glycan.  
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Presumably, the pilin glycan inhibited the phagocytosis of PA1244.  To determine the logic 
behind this occurrence, the nature of the pili must be examined.  It has been shown that the pili 
of P. aeruginosa contain highly hydrophobic domains (Mattick, 2002).  These domains can 
generate a net hydrophobic attractive force that mediates attachment of piliated bacteria to cell 
surfaces (Speert et al., 1986).  Specifically, these hydrophobic forces can mediate attachment of 
the bacteria to a phagocytic cell.  Such action would enhance the phagocytosis of piliated strains.  
However, because of the attachment of the sugars onto the pilus of PA1244, this net hydrophobic 
attractive force is disrupted.  Glycosylation of the pili creates a hydrophilic, acidic environment 
around PA1244.  This hydrophilic nature of the pilin glycan may have created a repulsive rather 
than an attractive force thereby inhibiting the bacteria from attaching to the white blood cells.  If 
attachment does not occur, phagocytosis is very unlikely to occur.  
Furthermore, because the glycan is evenly distributed over the entire pilus fiber (Jewell, 
2004), it is likely that the binding sites along the pilus are hidden.  As previously explained, this 
would inhibit any component of the host immune system from binding to the glycosylated pili 
and engulfing it.   
When analyzing the results of this immunological assay, one might ask why some PA1244 
bacteria were still phagocytosed.  The answer lies in the fact that all cells are not exactly the 
same.  Even though it has been proven that sugars inhibit attachment and phagocytosis, it is 
probable that some sugars may not display as great of a hydrophilic force as others.  If this holds 
true, the P. aeruginosa cells with weaker hydrophilic forces may still be attracted to the white 
blood cells and undergo phagocytosis.  In addition, every white blood cell does not exhibit the 
same attractive force nor does it demonstrate identical immunological capabilities.  For instance, 
one white blood cell may be larger than normal providing more surface area for attachment.  
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Also, some white blood cells may have stronger attractive forces increasing the chances of the 
bacteria attaching to the white blood cell and undergoing phagocytosis.   
Future experiments could be conducted using the same procedure as described in this work; 
however, the coverslips could be analyzed via a transmission electron microscope or a scanning 
electron microscope.  These high-power devices will allow for a more detailed image of the 
engulfed bacteria inside of the white blood cell.  In addition, a similar study to the present work 
could be conducted to determine if time is a factor in nonopsonic phagocytosis.  Samples can be 
analyzed from the phagocytic environment containing the bacteria and the white blood cells 
every 30 minutes.  This would provide a rough estimation of the rate of phagocytosis.   
Overall, the results of the LD50 studies, the competition assay, and the nonopsonic 
phagocytosis assay demonstrate that the pilin glycan serves as a virulence factor of PA1244.  By 
effectively inhibiting the action of the host immune system, the glycan allows for the successful 
colonization of the host.   
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VI. Appendix 
 
Bacterial Strain 
 
 
Volume Plated
 
Number of Colonies
 
1244G7(pUCP19) 
 
 
200 µl 
 
345 
 
1244G7(pCUP19) 
 
 
400 µl 
 
300 
 
1244G7(pUCP19exoUspcU) 
 
 
200 µl 
 
75 
 
1244G7(pUCP19exoUspcU) 
 
 
400 µl 
 
30 
 
1244-47(pUCP19) 
 
 
200 µl 
 
 
4665 
 
1244-47(pUCP19) 
 
 
400 µl 
 
4635 
 
1244-47(pUCP19exoUspcU) 
 
 
200 µl 
 
870 
 
1244-47(pUCP19exoUspcU) 
 
 
400 µl 
 
1267.5 
 
1244(pUCP19) 
 
 
200 µl 
 
17520 
 
1244(pUCP19) 
 
 
400 µl 
 
10440 
 
1244(pUCp19exoUspcU) 
 
 
200 µl 
 
6465 
 
1244(pUCP19exoUspcU) 
 
 
400 µl 
 
6270 
 
Table A1. Transformation Efficiency Colony Counts – The number of colonies has been 
adjusted to accommodate for the varying volume of cells plated. 
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(a) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244 
7 x 106 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
TNTC 
 
21, 15 
 
1, 2 
 
 
(b) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244 
3 x 106 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
TNTC 
 
10, 10 
 
1, 0 
 
 
(c) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244G7 
7.5 x 106 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
TNTC 
 
11, 17 
 
2, 2 
 
 
 
(d) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244G7 
4 x 106 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
71, 67 
 
5, 9 
 
0, 0 
 
Table A2 (Part 1). Colony Counts Used to Determine the Actual Inoculum Administered in 
the Short-Term LD50 Studies without the exoU Gene.  (TNTC = Too Numerous To Count). 
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(e) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244-47 
1 x 107 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
TNTC 
 
25, 18 
 
1, 3 
 
 
 
(f) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244-47 
7 x 106 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
TNTC 
 
20, 15 
 
1, 1 
 
 
 
 
(g) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244-47 
5 x 106 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
TNTC 
 
16, 21 
 
3, 0 
 
 
Table A2 (Part 2). Colony Counts Used to Determine the Actual Inoculum Administered in 
the Short-Term LD50 Studies without the exoU Gene.  (TNTC = Too Numerous To Count). 
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(a) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244 
(pUCP19exoUspcU) 
1 x 107 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
TNTC 
 
25, 27 
 
6, 2 
 
 
(b) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244 
(pUCP19exoUspcU) 
1 x 106 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
45, 48 
 
5, 4 
 
1, 0 
 
 
 
(c) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244 
(pUCP19exoUspcU) 
5 x 105 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
17, 14 
 
2, 4 
 
0, 0 
 
 
 
(d) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244 
(pUCP19exoUspcU) 
1.0 x 105 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
5, 5 
 
0, 0 
 
0, 0 
 
 
Table A3 (Part 1). Colony Counts Used to Determine the Actual Inoculum Administered in 
the LD50 Studies Utilizing Strains Possessing the exoU Gene.  (TNTC = Too Numerous To 
Count). 
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(e) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244 
(pUCP19exoUspcU) 
1.0 x 104 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
8, 13 
 
2, 0 
 
1, 0 
 
0, 0 
 
 
 
(f) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244G7 
(pUCP19exoUspcU) 
1 x 107 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
TNTC 
 
TNTC 
 
23, 15 
 
 
 
(g) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244G7 
(pUCP19exoUspcU) 
1 x 106 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
TNTC 
 
24, 17 
 
2, 2 
 
 
 
(h) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244G7 
(pUCP19exoUspcU) 
9.0 x 105 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
14, 13 
 
2, 3 
 
0, 0 
 
 
Table A3 (Part 2). Colony Counts Used to Determine the Actual Inoculum Administered in 
the LD50 Studies Utilizing Strains Possessing the exoU Gene.  (TNTC = Too Numerous To 
Count). 
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(i) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244G7 
(pUCP19exoUspcU) 
1 x 105 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
10, 17 
 
1, 4 
 
0, 0 
 
 
 
(j) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244G7 
(pUCP19exoUspcU) 
1.0 x 104 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
23, 23 
 
2, 0 
 
1, 0 
 
0, 0 
 
 
 
(k) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244-47 
(pUCP19exoUspcU) 
1.0 x 107 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
TNTC 
 
55, 51 
 
4, 5 
 
 
 
(l) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244-47 
(pUCP19exoUspcU) 
5.0 x 106 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
TNTC 
 
42, 42 
 
6, 1 
 
 
Table A3 (Part 3). Colony Counts Used to Determine the Actual Inoculum Administered in 
the LD50 Studies Utilizing Strains Possessing the exoU Gene.   (TNTC = Too Numerous To 
Count). 
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(m) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244-47 
(pUCP19exoUspcU) 
1.0 x 106 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
16, 25 
 
5, 2 
 
0, 0 
 
 
 
(n) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244-47 
(pUCP19exoUspcU) 
5.0 x 105 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
3, 1 
 
0, 0 
 
0, 0 
 
0, 0 
 
0, 0 
 
0, 0 
* Plating Error.  Will use an average of the inoculum density above and below desired amount. 
 
 
(o) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244-47 
(pUCP19exoUspcU) 
1.0 x 105 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
46, 50 
 
9, 4 
 
1, 1 
 
0, 0 
 
 
 
Table A3 (Part 4). Colony Counts Used to Determine the Actual Inoculum Administered in 
the LD50 Studies Utilizing Strains Possessing the exoU Gene.  (TNTC = Too Numerous To 
Count). 
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(a) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244-47 
(pUCP19exoUspcU) 
1.5 x 107 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
18, 23 
 
2, 3 
 
1, 0 
 
 
(b) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244-47 
(pUCP19exoUspcU) 
1.5 x 106 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
21, 23 
 
4, 5 
 
1, 0 
 
0, 0 
 
 
(c) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244-47 
(pUCP19exoUspcU) 
6.5 x 105 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
15, 8 
 
1, 1 
 
1, 0 
 
0, 0 
 
 
(d) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244-47 
(pUCP19exoUspcU) 
5 x 105 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
45, 29 
 
3, 6 
 
1, 0 
 
 
Table A4 (Part 1). Colony Counts Used to Determine the Actual Inoculum Administered in 
the Long-Term LD50 Studies Utilizing 1244-47(pUCP19exoUspcU).  (TNTC = Too Numerous 
To Count). 
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(e) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244-47 
(pUCP19exoUspcU) 
3 x 105 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
23, 35 
 
3, 4 
 
1, 0 
 
 
 
(f) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244-47 
(pUCP19exoUspcU) 
1.5 x 105 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
20, 29 
 
3, 2 
 
1, 0 
 
0, 0 
 
0, 0 
 
 
 
(g) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244-47 
(pUCP19exoUspcU) 
1 x 105 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
13, 11 
 
1, 2 
 
0, 0 
 
 
 
(h) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244-47 
(pUCP19exoUspcU) 
1.5 x 104 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
27, 18 
 
1, 2 
 
0, 0 
 
0, 0 
 
0, 0 
 
0, 0 
 
 
Table A4 (Part 2). Colony Counts Used to Determine the Actual Inoculum Administered in 
the Long-Term LD50 Studies Utilizing 1244-47(pUCP19exoUspcU).  (TNTC = Too Numerous 
To Count). 
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(a) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244 
(pUCP19exoUspcU) 
5.0 x 105 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
TNTC 
 
298, 
250 
 
34, 30 
 
3, 4 
 
 
 
(b) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
1244G7 
(pUCP19exoUspcU) 
5.0 x 105 
CFU/20 µl 
(desired) 
 
 
Number of 
Colonies 
 
 
TNTC 
 
TNTC 
 
784, 
784 
 
110, 
110 
 
8, 8 
 
1, 0 
 
 
Table A5. Colony Counts Used to Determine the Actual Inoculum Administered in the 
Competition Assay.  (TNTC = Too Numerous To Count). 
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Lung Tissue Weights 
 
 
 
 
 
 
Lung Weight
Mouse #1 
Mouse #2 
 
Mouse #3 
 
Mouse #4 
 
Mouse #5 
 
Mouse #6
0.40 g 
 
0.28 g 
 
0.40 g 
 
0.32 g 
 
0.26 g 
 
0.37 g 
    
    
    
 
 
 
 
 
Table A6. Lung Tissue Weights Obtained in Competition Assay.  After removal from the 
mouse, each lung was weighed prior to homogenization.  As indicated, each mouse had a similar 
lung mass.  
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(a) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
Mouse #1 
Lungs 
TSA Cb250 
 
 
Number of 
Colonies 
 
 
TNTC 
 
692, 
564 
 
64, 62 
 
4, 6 
 
1, 1 
 
0, 0 
 
 
 
(b) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
Mouse #1 
Lungs 
TSA Cb250Gm100 
 
 
Number of 
Colonies 
 
 
TNTC 
 
37, 81 
 
9, 6 
 
1, 2 
 
0, 0 
 
0, 0 
 
 
 
(c) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
Mouse #2 
Lungs 
TSA Cb250 
 
 
Number of 
Colonies 
 
 
TNTC 
 
105, 
108 
 
10, 14 
 
0, 4 
 
0, 0 
 
0, 0 
 
 
 
 
(d) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
Mouse #2 
Lungs 
TSA Cb250 Gm100 
 
 
Number of 
Colonies 
 
 
266, 
224 
 
19, 9 
 
1, 3 
 
1, 0 
 
0, 0 
 
0, 0 
 
Table A7 (Part 1). Colony Counts Recovered from the Lungs of the Mice in the 
Competition Assay.  (TNTC = Too Numerous To Count). 
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(e) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
Mouse #3 
Lungs 
TSA Cb250 
 
 
Number of 
Colonies 
 
 
TNTC 
 
292, 
302 
 
67, 61 
 
6, 5 
 
0, 0 
 
0, 0 
 
 
 
(f) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
Mouse #3 
Lungs 
TSA Cb250Gm100 
 
 
Number of 
Colonies 
 
 
TNTC 
 
64, 46 
 
8, 12 
 
2, 0 
 
0, 0 
 
0, 0 
 
 
 
(g) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
Mouse #4 
Lungs 
TSA Cb250 
 
 
Number of 
Colonies 
 
 
TNTC 
 
145, 
150 
 
20, 17 
 
5, 5 
 
0, 0 
 
0, 0 
 
 
 
 
(h) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
Mouse #4 
Lungs 
TSA Cb250 Gm100 
 
 
Number of 
Colonies 
 
 
282, 
289 
 
16, 16 
 
4, 3 
 
0, 0 
 
0, 0 
 
0, 0 
 
Table A7 (Part 2). Colony Counts Recovered from the Lungs of the Mice in the 
Competition Assay.  (TNTC = Too Numerous To Count). 
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(i) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
Mouse #5 
Lungs 
TSA Cb250 
 
 
Number of 
Colonies 
 
 
253, 
296 
 
22, 23 
 
3, 3 
 
0, 0 
 
0,0 
 
0, 0 
 
 
 
(j) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
Mouse #5 
Lungs 
TSA Cb250Gm100 
 
 
Number of 
Colonies 
 
 
33, 38 
 
3, 5 
 
1, 0 
 
0, 0 
 
0, 0 
 
0, 0 
 
 
 
(k) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
Mouse #6 
Lungs 
TSA Cb250 
 
 
Number of 
Colonies 
 
 
TNTC 
 
296, 
250 
 
41, 30 
 
3, 0 
 
0, 0 
 
0, 0 
 
 
 
 
(l) 
 
Dilution 
 
 
10-1
 
10-2
 
10-3
 
10-4
 
10-5
 
10-6
 
Mouse #6 
Lungs 
TSA Cb250 Gm100 
 
 
Number of 
Colonies 
 
 
488, 
640 
 
23, 22 
 
4, 4 
 
0, 0 
 
0, 0 
 
0, 0 
 
Table A7 (Part 3). Colony Counts Recovered from the Lungs of the Mice in the 
Competition Assay.  (TNTC = Too Numerous To Count). 
 
 102
 
 
 
 
 
Phagocytosis Counts 
 
 
E. coli HB101 
 
 
PAwbpL
34 32 
27 25 
31 22 
25 28 
44 19 
25 21 
30 33 
22 26 
40 18 
46 16 
 
PA1244 
 
 
PA1244G7
2 5 
0 3 
6 12 
0 6 
0 10 
0 15 
0 12 
4 8 
0 13 
0 7 
 
 
 
Table A8. Number of Bacteria Phagocytosed per White Blood Cell in Nonopsonic 
Phagocytosis.  For each strain of bacteria, ten white blood cells were randomly chosen and 
assessed for ingested bacteria.  Strains E. coli HB101 and PAwbpL served as the controls due to 
their lack of an O-antigen.  As expected, PA1244G7 is more easily phagocytosed compared to 
PA1244. 
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